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1. GENERAL INTRODUCTION 
Pharmaceutical Analysis plays a major role today, and it can be considered as an 
interdisciplinary subject. Pharmaceutical Analysis derives its principles from various 
branches like chemistry, physics, and microbiology etc., Pharmaceutical Analytical 
techniques are applied mainly in two areas, viz quantitative analysis and qualitative 
analysis, although there are several other applications. 
Drugs and pharmaceuticals are chemicals or like substances, which are of organic, 
inorganic or other origin. Whatever may be the origin, we use some property of the 
medicinal agent to measure them quantitatively or qualitatively. Pharmaceutical 
Analytical techniques, which are being used, can be categorized as follows. 
Spectral Methods1, 2 
We use light absorption (or) emission characteristics of drugs. 
E.g. UV spectroscopy, IR spectroscopy, NMR spectroscopy, ESR spectroscopy, mass 
spectrometry, flourimetry. 
Chromatographic Methods 
We use affinity or partition coefficient differences between drugs. 
E.g. Thin Layer Chromatography, High Performance Liquid Chromatography, Gas 
chromatography, Paper Chromatography. 
Electro Analytical Techniques 
Based on the electrochemical property of drugs. 
e.g., Potentiometer, Conductometry, Polarography, Amperometry, Paper     
Electrophoresis. 
Radio Active Methods 
It involves measurement of the intensity of the radiation from a naturally radioactive 
substance or an induced radioactive substance arising from exposure of the sample to a 
neutron source. 
e.g., Radio Immuno Assay 
Physical Methods 
We measure some physical characteristics of drugs 
e.g. Differential Thermal Analysis, Differential Scaning Calorimetry, Thermo 
Mechanical Analysis, Thermo Gravimetric Analysis. 
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Titrimetric Methods 
e.g. Non- aqueous titrations, redox titrations, diazotization titrations and complexometric 
titrations. 
X-Ray Methods  
When high speed electrons collide with a solid target, X-rays are produced. From the 
remittent x-ray emission, it is possible to identify certain emission peaks, which are 
characteristic of elements contained in the target.  The wavelength of the peaks can be 
related to the atomic numbers of the elements producing them 
In recent years, several analytical techniques have been evolved that combine two or 
more methods into one called “hyphenated” technique eg: GC/MS, LC/MS etc. The 
complete analysis of a substance consists of four main steps. 
1. Sample preparation / Sampling 
2. Dissolution of the sample, conversion of the analyte into a form suitable for 
measurement. 
3. Measurement 
4. Calculation and interpretation of the measurement 
Factors affecting the choice of analytical methods 
Possible interference from components of the material other than those of interest. 
¾ The concentration range, which needs to be investigated 
¾ The accuracy required. 
¾ The facilities available. 
¾ The time required for complete analysis. 
¾ Problem arising from the nature of the material 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
One of the early problems with liquid state chromatography was the slow rate at which 
analysis took place. Early methods use gravity feed, and it was not uncommon for an 
analysis to take several days to complete. This led not only to great delay but also the 
excessive time on the column and thus inevitably led to loss of resolution by diffusion 
and soon. Consequently for a number of year’s liquid chromatography was not widely 
used as a means of separating organic compounds. This problem was largely overcome 
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by the advent of High Performance liquid Chromatography (HPLC). In this system the 
pressure is applied to the column forcing the mobile phase through at much higher rate.  
The pressure is applied using pumping system. The action of the pump is critical, since it 
must not pulsate and mix up the sample being separated in the solvent, causing it to lose 
resolution. Development of pumps have proceeded quite quickly over the last several 
years, and now it is possible to achieve good separation under the condition required for 
HPLC. All of the factors affecting separation in liquid chromatography apply to HPLC. 
The factors affecting plate height, the sample distribution between the stationary and 
mobile phase and the selection of stationary and mobile phase still pertain even under the 
conditions of HPLC. The principal advantage of the system is the speed at which 
separations take place.  
 
Principle of separation in HPLC 3, 4, 5 
The principle of separation can be either adsorption or partition. 
Types of HPLC techniques 
Based on modes of separation   
1. Reversed phase chromatography 
2. Normal phase chromatography 
Based on principle of separation 
1. Adsorption chromatography  
2. Partition chromatography 
3. Ion exchange chromatography  
4. Ion pair chromatography  
5. Size exclusion or Gel permeation chromatography  
6. Affinity chromatography  
7. Chiral phase chromatography 
Based on elution technique  
1. Isocratic Separation  
2. Gradient Separation  
Based on the scale of operation  
1. Analytical HPLC  
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2. Preparative HPLC  
Based on the type of analysis  
1. Qualitative Analysis  
2. Quantitative Analysis  
Advantages of HPLC  
¾ Efficient, highly selective and widely applicable  
¾ Only small sample is required.  
¾ Ordinarily nondestructive to sample.  
¾ Readily adaptable to Quantitative analysis  
¾ Simple and inexpensive equipment compared to GC.  
¾ Can accommodate nonvolatile and thermally unstable samples.  
¾ Generally applicable to inorganic ions.  
THEORY 
Chromatography is an analytical method that finds wide application for the separation, 
identification and determination of chemical components in complex mixtures. This 
technique is based on the separation of components in a mixture (the solute) due to the 
difference in migration rates of the components through a stationary phase by a liquid 
mobile phase. 
Following parameters are used in the chromatogram optimization – 
1. Resolution 
2. Capacity Factor 
3. Efficiency Factor 
4. Column Selectivity 
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tm   = retention time of void volume 
tm1  = retention time of peak1 
tm2  = retention time of peak 2 
Separation factor α can be calculated by dividing the two k1’s of two peaks. α value 
ranges from 1.0-2.0. 
Components with α = 1.0 overlap completely and those with α > 2.0, can be separated by 
a separatory funnel. Larger α’s are needed in HPLC only in preparative runs. 
Ranges of chromatography parameters 
 
S.No PARAMETER RANGE 
  1 
 
 
  2 
 
  3 
Capacity factor (k’ ) 
Analytical  
Preparative  
Efficiency factor (N) 
 
Selectivity (or) 
Separation factor (α) 
 
1-8 
4-12 
Hundreds (poor resolution) to 10’s of 1000’s 
(good resolution) 
1-2. At α = 1, peaks overlap completely 
 
INSTRUMENTATION 
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SYSTEM COMPONENTS 
Solvent delivery system 
The mobile phase is pumped under pressure from one or several reservoirs and flows 
through the column at a constant rate. With micro particulate packing, there is a high-
pressure drop across a chromatography column. Eluting power of the mobile phase is 
determined by its overall polarity, the polarity of the stationary phase and the nature of 
the sample components. For normal phase separations eluting power increases with 
increasing polarity of the solvent but for reversed phase separations, eluting power 
decreases with increasing solvent polarity. Optimum separating conditions can be 
achieved by making use of mixture of two solvents.  
The solvent delivery system has three basic functions: 
¾ Provide accurate and constant flow through the flow channel. 
¾ Provide accurate mobile phase compositions. 
¾ Provide the force [pressure] necessary to push the mobile phase through the 
tightly packed column. 
A solvent delivery system must provide accurate, reproducible flow and composition. 
System must also provide the force necessary to push the mobile phase through the 
tightly packed column. In addition, the solvent delivery system can’t produce pressure 
pulsations. So damping unit is usually customary.  
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Damping units 
The purpose of the damping unit is to reduce pressure pulsations caused by the action of 
the pump. A damping unit consists of a diaphragm separating the mobile phase from a 
compressible liquid. 
Pump 
The most important component of HPLC in solvent delivery system is the pump, because 
its performance directly effects the retention time, reproducibility and detector sensitivity.  
 
  
SAMPLE INTRODUCTION SYSTEM 
A sample introduction system is required to deliver the sample to the head of the HPLC 
column. The sample must be delivered without stopping or disturbing the mobile phase 
flow to the column. Sample injector must be very accurate and precise in its delivery. The 
sampler must also display low memory effects (carry-over). 
Injectors are used for reproducible introduction of the sample volume into the mobile 
phase flow.  
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Column              
Many separations depend not only on the column material and mobile phases but also on 
the column Temperature. In such cases, column temperature stability is the dominating 
factor for the elution order. The heart of the system is the column. In order to achieve 
high efficiency of separation, the column material (micro-particles, 5-10 μm size) packed 
in such a way that highest numbers of theoretical plates are possible.  
 
 
Silica (SiO2 X H2O) is the most widely used substance for the manufacture of packing 
materials. It consists of a network of siloxane linkages (Si-O-Si) in a rigid three 
dimensional structure containing inter connecting pores. The silanol groups on the 
surface of silica give it a polar character, which is exploited in adsorption 
chromatography using non-polar organic eluents. Silica can be drastically altered by 
reaction with organo chloro silanes or organo alkoxy silanes giving Si-O-Si-R linkages 
with the surface. The attachment of hydrocarbon change to silica produces a non-polar 
surface suitable for reversed phase chromatography where mixtures of water and organic 
solvents are used as eluents. The most popular material is octadecyl-silica (ODS-Silica), 
which contains C18 chains, but materials with C2, C6, C8 and C22 chains are also available. 
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DISSOLUTION 6, 7, 8 
Dissolution is a process in which a solid substance solubilizes in a given solvent that is 
mass transfer from the solid phase to the liquid phase. Pharmaceutical solid dosage forms 
and solid-liquid dispersed forms, on administration, under dissolution in biological 
media, followed by absorption of drug entity into systematic circulation. In determining 
the dissolution rate of drug from solid dosage forms, under standardized conditions, one 
has to consider several physicochemical processes in addition to the process involved in 
the dissolution of pure chemical substances.  
The following factors that influence the dissolution characteristic of the drug. 
¾ Physical characteristics of dosage form 
¾ Wet ability of the dosage unit 
¾ Penetration ability of the dissolution medium 
¾ Swelling process 
¾ Disintegration and disaggregation of the dosage form  
Wagner proposed the scheme regarding the process involved in the dissolution of solid 
dosage forms is given as follows: 
 
Tablet or capsule          Granules or Aggregates          Fine particles 
                                                  
                       
             Dissolution            Dissolution                                        
 
                                       
Drug in solution 
 (In vitro or In vivo) 
The Wagner scheme was later modified to incorporate other that precedes the dissolution 
process of the solid dosage forms. Cartesian proposed a scheme incorporating the 
following sequence. 
1. Initial Mechanical Lag  
2. Wetting of the dosage form 
3. Penetration of the dissolution medium into dosage form 
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4. Disintegration 
5. Disaggregation ion of the dosage form 
6. Dissolution 
7. Occlusion of some particles of the drug. 
It is apparent from the Wager’s schematic representation that the rate of dissolution of the 
drug can become the rate-limiting step before the drug appears in blood. When the 
dosage form is placed into gastrointestinal tract in solid form, for the drug enters to the 
blood stream, there are two possible rate-limiting steps. 
1. Freely purified water-soluble drugs will tend to dissolve rapidly, making the 
passive diffusion of the drug and or the active transport of the drug as the rate-
limiting step for the drug to enter the blood stream. 
2. Conversely, the rate of absorption of poorly soluble drug will be limited by the 
rate of dissolution of the drug or disintegration of dosage form. 
Discriminative dissolution method 
A method that is sensitive to change in formulation, raw material characteristics and 
critical manufacturing variable is said to be discriminative dissolution method. 
In official or QC release method, the two products may shows same dissolution profile 
but when discriminative dissolution method is used, we can differentiate the formulation 
profile by release profile Once a discriminative dissolution method is developed, an in 
vitro-in vivo correlation can be established which could forecast the bioavailability of all 
the formulation developed during the product development. Factors like type of apparatus 
used, rpm, volume of dissolution media should be considered for the development of 
discriminative dissolution method. For study, we have selected rpm as one of the 
important factor for discriminative dissolution method. 
The important parameters for the development of dissolution methods are 
1. The pH dependent solubility  
2. Stability 
Applications 
Discriminative dissolution method is an important tool in prototype formulation and 
development. Its applications are as follows: 
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It cans differentiate the change in formulation, which is due to variation in manufacturing 
process like granulation time, mixing time etc. 
It predicts in-vivo behavior. 
Once in vitro – in vivo correlation (IVIVC) is established, bioavailability study can be 
avoided, which can save the time and money in research work. 
Theories of dissolution 
Several theories to explain drug dissolution have been proposed. Some of the important 
ones are:  
1. Diffusion layer model / Film theory 
2. Danckwert’s model / Penetration or Surface renewal theory, and 
3. Interfacial barrier model / Double barrier or Limited solvation theory. 
Classification of dissolution testing devices 
1. USP Apparatus I (Basket Type) 
2. USP Apparatus II (Paddle Type)  
3. USP Apparatus III (Reciprocating Cylinder) 
4. USP Apparatus IV (Flow-Through Cell) 
5. USP Apparatus V (Paddle over disk)                                            
6. USP Apparatus VI (Cylinder) 
7. USP Apparatus VII (Reciprocating Holder) 
Dissolution medium 
The volume of the dissolution medium is generally 500, 900, or 1000mL. Sink conditions 
are desirable but not mandatory. An aqueous medium with pH range 1.2 to 6.8 (ionic 
strength of buffers the same as in USP) should be used. To simulate intestinal fluid (SIF), 
a dissolution medium of pH 6.8 should be employed. A higher pH should be justified on 
a case-by-case basis, and in general, should not exceed pH 8.0. To simulate gastric fluid 
(SGF), a dissolution medium of pH 1.2 should be employed without enzymes. The need 
for enzymes in SGF and SIF should be evaluated on case-by-case basis and should be 
justified. Recent experience with gelatin capsule products indicates the possible need for 
enzymes (pepsin with SGF and pancreatic with SIF) to dissolve pellicles, if formed, to 
permit the dissolution of the drug. Use of water as a dissolution medium also is 
discouraged because test conditions such as pH and surface tension can vary depending 
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on the source of water and may change during the dissolution test itself, due to the 
influence of the active and inactive ingredients. For water insoluble or sparingly water 
soluble drug products, use of a surfactant such as sodium lauryl sulfate is recommended 
(Shah, 1995). The need for and the amount of surfactant should be justified. Use of a 
hydro alcoholic medium is discouraged. 
Agitation 
In general, mild agitation conditions should be maintained during dissolution testing to 
allow maximum discriminating power and to detect product with poor in vivo 
performance. Using the basket method, the common agitation (or stirring speed) is 50-
100 rpm; with the paddle method, it is 50-75 rpm. 
FACTORS AFFECTING DISSOLUTION EXTENT 
Equation [1] describes factors controlling extent of dissolution. 
Maximum Dissolvable Dose = V × Cs / sink     [1] 
Where, 
    V      = Dissolution medium volume 
    Cs     = Saturated solubility of the compound in the medium 
    Sink    = Sink condition factor 
To increase the maximum dissolvable dose, one needs to increase the dissolution media 
volume, change the media to increase the saturation solubility of the compound, or 
reduce the dissolution sink requirements.  
Media volume 
There are several ways to increase the dissolution media volume. Using 4- liter vessel is 
relatively uncommon, but they are available from vendors. This offers a potential 4-fold 
enhancement in maximum dissolvable dose over the standard 1-liter vessels. 
Saturation solubility 
The standard way to affect the saturation solubility of the drug in the dissolution media is 
to change the media, typically by adjusting the pH, adding a surfactant, or in rare cases, 
using non-aqueous solvents. 
pH 
If the compound is ionizable, adjusting the pH of the dissolution media is a very effective 
way to increase solubility. 
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Surfactants 
Two factors to consider when evaluating surfactants are cost and concentration needed. If 
the dissolution assay is to be run in a Quality Control setting, choosing an inexpensive 
surfactant will be important to keep overall assay costs down. Examples of inexpensive 
surfactants are sodium dodecyl sulfate or SDS (also referred to as sodium lauryl sulfate or 
SLS) for an anionic surfactant, cetyltrimethylammonium bromide or CTAB for a cationic 
surfactant, and the polysorbates or Tweens for a non-ionic surfactant. To get any 
substantial solubility enhancement, the surfactant concentration must be at least above the 
critical micelle concentration or CMC. The CMC will depend upon, among other things, 
the surfactant itself and the ionic strength of the media. The amount of surfactant needed 
depends on the CMC and the degree to which the compound partitions into the surfactant 
micelles. 
If the compound is ionizable, surfactants concentration and pH may be varied 
simultaneously, and the combined effect can substantially change the solubilization 
ability of the dissolution media 
Non-aqueous solvents 
The use of non-aqueous solvent for dissolution media is unconventional. However, if 
aqueous-based methods for achieving solubility have been exhausted, use of hydro-
alcoholic media may be the best alternative. For example, the USP24-NF19 monograph 
for cortisone acetate tablets lists 30% isopropanol, 70% 0.01 N HCl as the dissolution 
media, and water/alcohol mixtures have been used as media for drug release testing of 
topical formulations using the Franz-diffusion cell apparatus. 
Sink conditions 
Sink condition refer to the excess solubilizing capacity of the dissolution medium. Most 
sources recommend at least 3X (three times the volume needed to completely solubilize 
the dose) and some sources recommend 5X and even 10X. 
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METHOD DEVELOPMENT 9, 10, 11 
Every day many chromatographers face the need to develop a high –performance liquid 
chromatographic separation. Whereas individual approaches may exhibit considerable 
diversity, the method development often follows the series of steps summarized. 
There exists today a good practical understanding of chromatographic separation and 
how it varies with the sample and with experimental conditions .Any systematic approach 
to HPLC method development should be based on the knowledge of the chromatographic 
process. In most cases a desired separation can be achieved easily with only a few 
experiments .In other cases, a considerable experimentation is needed. A good method 
development strategy should require as many experimental runs as are necessary to 
achieve the desired final result. 
STEPS IN HPLC METHOD DEVELOPMENT 
1. Information on sample, and  separation goals 
2. Need for special HPLC procedure 
3. Choose detector and detector settings 
4. Choose LC method; preliminary run; estimate the best separation conditions. 
5. Optimize separation conditions. 
6. Check for problems 
7. Recover purified material 
a. Quantitative calibration 
b. Qualitative method 
8. Validate method to release to routine laboratory. 
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WHATS IS KNOWN BEFORE STARTING 
NATURE OF THE SAMPLE 
¾ Number of compounds present 
¾ Chemical structure of compound 
¾ Molecular weight of compound 
¾ pKa values of compound 
¾ UV spectra of compound 
¾ Concentration range 
¾ And sample solubility. 
Separation goals 
Is the primary goal quantitative analysis, the detection of an substance, the 
characterization of unknown sample components (or) isolation of purified material. 
Is it necessary to resolve all sample components 
SAMPLE PRETREATMENT AND DETECTION  
Sample comes in various forms  
¾ Solutions ready for injection 
¾ Solids that must first be dissolved or extracted 
¾ Samples that require sample pretreatment to remove interferences and/or protect 
the column or equipment from damage. 
¾ Solutions that require dilution, buffering, addition of internal standard or other 
volumetric manipulation. 
Most samples for HPLC analysis require weighing and/ or volumetric dilution before 
injection. 
Some samples require a partial separation (pretreatment) prior to HPLC because of need 
to remove interferences, concentrate sample analyte, or eliminate column killers. This 
means that it is important to know the nature of the sample matrix and the probable 
concentrations of various analyte, in many cases the development of an adequate sample 
pretreatment procedure can be more challenging than achieving a good HPLC separation. 
Finally, method precision and accuracy are frequently determined by the sample 
pretreatment procedure. A sample pretreatment procedure should provide quantitative 
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recovery of analyte, involves a minimum number of steps, and be easily automated. 
Quantitative (99+ %) recovery of each analyte enhances sensitivity and assay precision.  
PRELIMINARY PROCESSING OF SOLID SAMPLES 
Reducing sample particle size 
It is desirable that solid samples be reduced in particle size since finely divided samples 
are  
1. More homogenous , allowing more representative sampling with greater precision 
and accuracy and 
2. Dissolve faster and are easier to extract because of their greater surface area. 
Methods for reducing sample particle size are blending, chopping, crushing, grinding, 
homogenizing, macerating, milling, mincing, pressing, pulverizing, sieving. 
EXTRACTION 
Extraction methods for solid samples 
¾ Solid –liquid extraction 
¾ Soxhlet extraction 
¾ Forced-flow leaching 
¾ Homogenization 
¾ Sonication 
¾ Dissolution 
¾ Accelerated solvent extraction 
¾ Automated soxhlet extraction 
¾ Supercritical fluid extraction 
¾ Microwave-assisted extraction 
¾ Thermal extraction 
DRYING THE SAMPLE 
Solid samples are often received for analysis in a damp or wet mass. Removal of water or 
drying the sample to constant weight is usually necessary for reliable assay. 
Hydrophobic organic samples require heating, since water absorption is minimal, for 
hygroscopic or reactive samples, drying in vacuum desiccators is recommended. Freeze 
drying (lyophilization) often used to preserve the integrity of heat sensitive samples 
(especially biological) 
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FILTRATION 
Particulates should be removed prior to injection because of their adverse effect on 
column life. The most common methods for removing of particulates from the sample are 
filtration, centrifugation, and sedimentation. A variety of membrane materials and 
different nominal porosities and dimensions are available for filtration. For most samples 
encountered in HPLC, filters in the range 0.25-2.0µm nominal porosities are 
recommended .Membranes with 0.25µm pores remove the smallest of particulates. 
DETECTION 
Before the first sample is injected during HPLC method development we must be 
reasonably sure that the detector selected will sence all sample components of interest. 
Variable wavelength ultraviolet detectors normally are the first choice, because of their 
convenience and applicability for most samples. For this reason, information on the UV 
spectra can be an important aid for method development.UV spectra can be found in the 
literature, estimated from the chemical structures of sample components of interest, 
measured directly or obtained during HPLC separation by means of a photo diode array 
(PDA) detector. When the UV response of the sample is inadequate, other detectors are 
available (fluorescence, electrochemical, etc,) 
GETTING STARTED ON METHOD DEVELOPMENT         
The only remaining decision before the first sample injection is the percent organic in the 
mobile phase (%B). One approach is to use an isocratic mobile phase of some average 
solvent strength ( eg.,50%B).A better alternative is to use a very strong mobile phase first 
(eg., 80 to 100% B) ,then reduce the % B as necessary. An alternative to initial isocratic 
separation is the use of gradient elution. 
IMPROVING THE SEPARATION 
The separation achieved in the first one or two runs usually will be less than adequate. 
After a few additional tries, it may be tempting to accept a marginal separation, especially 
if no further improvement is observed .However experienced workers realize that a good 
separation requires more than minimal resolution of the individual sample bands, 
particularly for a routine procedure used to analyse a number of samples.  
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SEPARATION GOALS IN HPLC METHOD DEVELOPMENT  
Resolution – precise and rugged method quantitative analysis requires that Rs be greater 
than 1.5 
Separation time- < 5 -10 min is desirable for routine procedures 
Quantitation - ≤ 2% (1 SD) for assay, ≤ 5%for less-demanding analyses, ≤ 15% for trace 
analysis. 
Pressure- < 150 bar is desirable, < 200 is usually essential (new column assumed) 
Peak height-narrow peaks are desirable for larger signal/noise ratios. 
Solvent consumption- minimum mobile phase use per run is desirable 
 
REPEATABLE SEPARATION 
It is important to confirm that each chromatogram can be repeated, as the experimental 
runs described being carried out. When changing conditions (mobile phase, column, 
temperature) between method development experiments, enough time must elapse for the 
column to come in to equilibrium with the new mobile phase and temperature .Usually 
column equilibrium is achieved after passage of 10 to 20 column volumes of the mobile 
phase through the column. However, this should be confirmed by carrying out a repeat 
experiment under the same conditions. When constant retention times are observed in 
two such back-to–back experiments (±0.5% or better)Column equilibration can be 
extremely slow for certain reversed-phase HPLC conditions ; addition of basic modifiers 
or ion pair reagents to the mobile phase, the use of Tetrahydrofuran as solvent or the   use 
of mobile phase without organic solvent. 
COMPLETING THE HPLC METHOD  
The final procedure should meet all the goals that were defined at the beginning of 
method development. The method should also be robust in routine operation and usable 
by all laboratories and personnel for which it is intended. 
 
Completing the method 
1. Preliminary data to show required method performance. 
2. Written assay procedures developed for use by other operators. 
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3. Systematic validation of method performance for more than one system or 
operator , using samples that cover the expected range in composition and analyte 
concentration; data obtained for day –to – day  and interlaboratory operation. 
4. Data obtained on expected life of column and column-to-column reproducibility. 
5. Deviate results studied for possible correction of hidden problems. 
6. All variables (temperature, mobile phase, composition, etc) studied for effect on 
separation; limits defined for these variables; remedies suggested for possible 
problems (poor resolution of key band pair, increased retention for last band with 
longer run times). 
CHECKING FOR PROBLEMS  
Low plate number – poor choice of column, secondary retentions, poor peak shape. 
Column variability- poor choice of column, secondary retentions effects. 
Short column life- poor choice of column, need for sample pretreatment      ,3> pH > 7. 
Retention drift –insufficient column equilibration, need for sample pretreatment, loss of 
bonded phase. 
Poor quantitative precision- need for better calibration, identification of sources of 
error. 
New interference peaks discovered- initial separation inadequate or initial samples not 
representative. 
METHOD RUGGEDNESS 
A rugged method is one that tolerates minor variations in experimental conditions, can be 
run easily by an average chromatographer, and does not require an identical HPLC 
system for its use. Rugged methods are essentially trouble free and transferable. 
Ruggedness can also be designed into a method by studying the effects of different 
variables on the separation. 
  
METHOD VALIDATION13, 14 
Then word validation simply means, “Assessment of validity” or action of proving 
effectiveness.  “The objective of validation of an analytical procedure is to demonstrate 
that it is suitable for its intended purpose.” 
      -ICH Guideline Federal 
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Method Validation = Error assessment 
Significance of method validation  
The quality of analytical data is a key factor in the success of a drug development 
programme. The process of method development and validation has a direct impact on 
the quality of these data. 
¾ To trust the method. 
¾ Regulatory requirement. 
Method validation is required for the following reasons 
¾ Assuring quality 
¾ Achieving the acceptance of the product by International Agencies 
¾ Mandatory requirement purpose for accreditation as per ISO 19025 guidelines. 
¾ Mandatory requirement for registration of any pharmaceutical product or 
pesticide formulation 
¾ Validated methods are only applicable for proficiency testing. 
Analytical methods should be validated unless the method employed is included in the 
relevant pharmacopoeia or other recognized standard reference. 
VALIDATION PARAMETERS 
SPECIFICITY  
Specificity is the ability to asses unequivocally the analyte in the presence of 
components, which may be expected to be present. 
LINEARITY  
The linearity of an analytical procedure is its ability (within a given range) to obtain test 
results, which are directly proportional to the concentration (amount) of analyte in the 
sample. In order to determine the quantity of any analyte present in unknown sample, 
some kind of relationship (mathematical/empirical) between concentration and response 
was essential. Response should be direct proportion to the concentration. 
LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION 
LOD 
Lowest amount of analyte in a sample that can be detected but not necessarily quantities, 
under the stated experimental conditions (LOD). 
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LOQ 
Lowest amount of analyte in a sample, which can be quantitatively, determined with 
suitable precision and accuracy (LOQ). SD of response (σ) & Slope(S): Linearity curve 
was prepared with a series of working standard solutions at different concentrations (3 
concentrations below 50% of specification level and 3 more concentration above 50% 
specification level were performed) 
RSD CRITERIA         
Series of working standard solutions of different concentrations below to specification 
level were prepared (generally about 10%, 20%, 30%, 40% and 50% of the specification 
concentration) and injected six replicate injections into HPLC. Precision should be 
established (if predicted from other than RSD criteria) at LOQ and LOD level as per ICH, 
USP& EP guidelines. The solution was prepared at predicted concentration (for 
LOQ/LOD) and injected six replicates as per methodology.  
ACCURACY 
The accuracy of an analytical procedure express closeness of agreement between the 
value, which is accepted either as a conventional true value or an accepted reference 
value and the value found. 
Accuracy was usually determined in one of four ways: 
¾ The procedure was applied to the known concentration of reference sample and 
the measured value to the true value was compared (defined by the organization, 
from which the sample received ) 
¾ The test results obtained were compared by the analytical procedure which was 
proved to be accurate with the results obtained from an existing alternate method 
that was known to be accurate 
¾ Spiking concept, by spiking either analyte/impurities into sample matrix was the 
other 
Recovery concept-standard addition approach. This approach was applicable, if it was not 
possible to prepare a blank sample matrix without the presence of the analyte 
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PRECISION 
Precision is the measurement of how close the data values to each other for a number of 
measurements under the same analytical conditions. Precision may be considered at three 
levels according to ICH 
¾ Repeatability 
¾ Intermediate precision 
¾ Reproducibility 
REPEATABILITY  
Precision under same operative conditions (with- in a laboratory over a short period of 
time using the same analyst with the same equipment) 
Measurement/ Injection repeatability (system precision). 
Method repeatability (Method precision) 
INTERMEDIATE PRECISION (RUGGEDNESS) 
Precision under different laboratory conditions (within-laboratory variation, as on 
different days, or with different analysts, or equipment’s within the same laboratory 
REPRODUCIBILITY 
Precision between laboratories/intermediate precision can be considered during the 
standardization of a procedure before it i.e. submitted to the pharmacopoeia. 
RANGE  
The range of an analytical procedure is the interval between the upper and lower 
concentrations (amounts) of analyte in the sample (including these concentrations) for 
which it has been demonstrated that the analytical procedure has a suitable level of 
precision, accuracy and linearity. The range of an analytical procedure was the 
concentration interval over which acceptable accuracy, precision and linearity were 
obtained. In practice, the range was determined using data from the linearity and 
accuracy studies. Assuming that acceptable linearity and accuracy (recovery) results were 
obtained as described earlier. The only remaining factor o be evaluated was precision. 
This precision data should be available from the triplicate analysis of spiked sample sin 
accuracy study. Hence to confirm the “range” of any analytical procedure, linearity 
studies alone not sufficient and accuracy at each concentration (minimum three 
concentration levels covering lower and upper levels) should be proved. 
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ROBUSTNESS 
Measure of its capacity to remain unaffected by small, but deliberate variations in method 
parameters and provides indication of its reliability during its normal usage. Varying 
method parameters within a realistic range and the quantitative influence of the variables 
was determined, and, if the influence of the parameter was within a previously specified 
tolerance, then, the parameter was said to be within the method’s robustness range. 
Typical variations included under Validation programme were 
¾ Flow rate (0.1%) 
¾ pH of the mobile phase(0.1 unit) 
¾ Temperature (2ºC) 
¾ % of Organic solvent (2%) 
¾ Wavelength (2 nm) 
RUGGEDNESS 
Method Ruggedness is defined as the reproducibility of results when the method is 
performed under actual use conditions. This includes different analysts, laboratories, 
columns, instruments, source of reagents, chemicals, solvents etc. Method ruggedness 
may not be known when a method is first developed, but insight is obtained during 
subsequent use of that method.  
STABILITY  
To generate reproducible and reliable results, the samples, standards and reagents used 
for the HPLC method must be stable for a reasonable time (e.g. one day, one week and 
one month depending upon need). For example, the analysis of even a single sample may 
require ten or more chromatographic runs to determine the system suitability, including 
standard concentrations to create a working analytical curve and duplicate or triplicate 
injections of the sample to be assayed. 
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VALIDATION PARAMETERS FOR ASSAY AND DISSOLUTION 
S. No VALIDATION PARAMETER ASSAY DISSOLUTION 
1 
System Suitability and 
System Precision 
9  9  
2 Specificity 9  9  
3 Precision 9  9  
4 Accuracy 9  9  
5 Linearity of Method 9  9  
6 Ruggedness 9  9  
7 Robustness 9  9  
8 Filter Validation 9  9  
9 Sink condition      X 9  
 
SINK CONDITION 
 Sink condition refers to the excess solubilizing capacity of the dissolution medium. 
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2. LITERATURE REVIEW 
 
1)  Hairong Wang15 et al has been developed a sensitive and specific liquid chromatography–
tandem mass spectrometric (LC–MS–MS) method to determine m-nisoldipine in rat plasma. 
Sample was pretreated by a single-step protein precipitation with acetonitrile, in contrast to the 
liquid–liquid procedure frequently used for the extraction of 1, 4-dihydropyridines from biologic 
samples. Separation of analyte and internal standard (I.S.) was performed on Symmetry RP-C18 
analytic column (50mm×4.6 mm, 3.5_m) with a mobile phase consisting of acetonitrile–water 
(80:20, v/v) at a flow rate of 0.5 ml/min.The API 4000 triple quadrupole mass spectrometer was 
operated in multiple reaction monitoring (MRM) scan mode using TurboIonSpray 
ionization(ESI) source. This method was sensitive with a lower limit of quantification (LLOQ) 
of 0.2 ng/mL, with good linearity (r≥0.9982) over the linear range of 0.2–20 ng/mL 
2)  R Heinig have developed16 et al a method for Determination of the enantiomers of 
nisoldipine in human plasma using high-performance liquid chromatography on a chiral 
stationary phase and gas chromatography with mass selective detection .this method has 
described that combines chiral HPLC and off-line GC with mass-selective detection for the 
quantitation of the enantiomers of nisoldipine [(+)-I] in human plasma. An isotope-labeled 
internal standard [nine-fold deuterated (+)-I] is used throughout the assay. The limit of 
quantification is 0.1 pg/l for each enantiomer. Enantioselective analysis was performed in 
subjects receiving the racemic drug in tablet form. In healthy volunteers the maximum 
Concentration and the area under the curve of the pharmacologically more active (+)-enantiomer 
were greater by 9-fold and 13-fold, respectively, compared to those of the (-)-enantiomer. After 
intravenous administration of (+)-I there were no relevant differences between the plasma 
concentrations of the enantiomers. 
 
3)  H Sugawara17 et al has studied Antioxidant Properties of Dihydropyridine in Isolated 
Sprague-Dawley rat hearts were perfused under constant flow conditions. Hearts were treated 
with H2O2 (500-600 PM), as buffer for 12 min including nisoldipine, nifedipine, or the optical 
isomers (+) - or (-)-nisoldipine. H2O2, was removed and perfusion continued with treatment 
buffers (10 min) followed by control buffer (20 min). Contractile function decreased following 
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perfusion with H2O2. Contractile function was protected in a concentration-dependent Manner 
(nisoldipine = 19, 26, 50, 63, and 78%; nifedipine = 23, 37, 55, 61, and 63% of pre-peroxide 
function, 0, 0.1, 0.5, 1.0, and 5 nM, respectively). There were no significant differences between 
equal concentrations of nisoldipine and nifedipine. Contractile function was equally protected by 
both (+) - and (-)-nisoldipine compared with vehicle-treated hearts (56, 67, and 16% of pre-
peroxide function, respectively). Biochemical analyses indicated that H2O2, damaged plasma 
membranes (increased lactate dehydrogenase leak) and caused lipid per oxidation (elevated 
tissue thiobarbituric acid reactive substances). Biochemical changes were equally reduced by 
nisoldipine and nifedipine treatments and by (+) - and (-)-nisoldipine. The treatment groups have 
widely differing ICI, v, a lues as calcium channel antagonists, yet they had equal effects in 
reducing oxidative injury, suggesting that this beneficial effect is not mediated by calcium 
antagonism. 
 
4)  M Gilar 18 et al has studied Enantiomer separation of dihydropyridine calcium antagonists 
with Cyclodextrins as chiral selectors: structural correlation in high-performance liquid 
chromatography and capillary electro migration separations (HPCE and MEKC). 
Chromatographic data of five dihydropyridine calcium antagonists obtained on three/3-CD chiral 
stationary phases in reversed-phase mode. This data were compared with those of capillary 
Electrophoresis using /3-CDs in the presence and absence of sodium dodecyl sulfate (SDS). 
Competition of separated compounds with SDS molecules for penetration into the CD cavity can 
limit their necessary interaction with the chiral selector and consequently even preclude 
enantiomer separation.  
 
5) J Mielcarek.19 et al Inclusion complexes of nifedipine and other 1.4-dihydropyridine 
derivatives with Cyclodextrins. IV. The UV study on photochemical stability of the inclusion 
complexes of nisoldipine, nimodipine, nitrendipine and nicardipine with beta-Cyclodextrins in 
the solution. J Chromatogr A. 666 (1-2); 241-8(1994)   
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6)  D Zimmer20 et al have developed a sensitive, selective and validated method for the 
enantioselective determination of (+) - and (-)-nisoldipine in rat, mouse and dog plasma 
following administration of nisoldipine racemate by chiral microbore high-performance liquid 
chromatography Combined with gas chromatography-mass spectrometry. The enantiomers of 
nisoldipine were quantitatively separated by high-performance liquid chromatography on a 250 x 
2 mm I.D. column containing tris (4_methylbenzoate) - modified cellulose on silica. The 
fractions containing either the (+) or (-)-enantiomer of the analyte and [13C4] ISTD were 
Analyzed by gas chromatography with mass-selective detection in the single-ion monitoring 
mode. The limits of determination and detection were 0.5 and 0.2 ng/ml, respectively, the total 
precision was 7% (R.S.D. at 5 and 50 ng/ml, n = 35) and the accuracy was 10% (0.5-100 ng/ml, 
n = 23). The sum of the concentrations of the enantiomers determined with this assay 
corresponds to the concentration of the racemate determined independently by capillary gas 
chromatography with Electron-capture detection (accuracy better than 15%, l-80 ng/ml).  
 
7) A Alvarez-Lueje21 et al The study by dc and d.p.p. reveals the appearance of four signals 
depending on pH. In contrast, the anodic response corresponds to the oxidation of the 1, 4-
dihydropyridine ring to generate the corresponding pyridine derivative. Both, cathodic (d.p.p.) 
and anodic signals (d.p.v.) were employed to develop analytical methodology for the 
determination of the drug. The repeatability of the measurements for both methods was adequate 
with R.S.D. of 1.4% (n_10) and 2.1% (n_10) for d.p.p. and d.p.v., respectively. Also recovery 
studies, 103.8% (R.S.D. 2.65%) by d.p.p. and 98.7% (R.S.D. 2.1%) by d.p.v. show that the 
accuracy and precision of the developed methods were adequate. The analytical methods were 
successfully applied to the determination of nisoldipine in both tablets and capsules. In addition, 
a preliminary study of the photo stability of nisoldipine (using both UV and artificial day light) 
was completed. The identity of the main electro active photo degradation products by GC with 
spectrometry detection is provided.  
 
8)  V Marinkovic22 et al have studied photochemical degradation of Nisoldipine ((9)3-isobutyl-
5-methyl-1, 4-dihydro-2, 6-dimethyl-4-(2-nitrophenyl)-pyridine-3, 5-dicarboxylate), whereby its 
4-(2-nitrosophenyl) pyridine analogue is obtained as the photolytic product, under daylight 
exposure by means of UV derivative spectrophotometry. The optimal instrumental parameters 
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(120 nm:min scan speed; 2 nm slit width; Dl_10 nm and 5 s response time) for analogue 
derivative spectra were established for amplitudes 1D285 and 2D291(measured to the baseline) 
of the nitroso analogue assay, as well as for 1D386 of the parent compound–nisoldipine assay. 
Using the first-order derivative spectrum, the minimum detectable amount of nitroso analogue in 
the presence of nisoldipine was equivalent to an impurity level of 5% and by the second-order 
derivative spectrum; the determination limit was equivalent to an impurity level of 2%. The 
degradation of nisoldipine followed within 30 days and the calculated maximal degradation rate 
was1.6% per day for nisoldipine raw material, but significantly lower values of 0.19 and 0.15% 
per day were obtained for Nisoldin®tablets (10 and 5 mg, respectively) 
 
9) Valentina D Marinkovic23 et al has studied photochemical degradation of solid-state 
nisoldipine, 1, 4-dihydropyridine calcium antagonist, under daylight and UV light conditions. 
Degradation products were identified by using the retention times of corresponding standards 
and quantified by high-performance liquid chromatographic method. HPLC experiments were 
carried out on a Hewlett Packard LC 1100 instrument, equipped with binary solvent pump G 131 
2A and variable detector G 1314A. An octadecyl silane column (Lichrosorb RP-18, 5 mm, 
250_/4 mm, Merck, Darmstadt, Germany) was used and methanol: water (60:40 v/v), pH 3.0 
adjusted with phosphoric acid was used as mobile phase. Flow rate 1 ml/min and loop 20 ml 
were used. The samples were monitored at 238 nm. The daylight illumination induced 
appearance of nitrosophenylpyridine, while formation of second degradation product, 
nitrophenylpyridine, was observed only upon UV light illumination. The photo degradation 
kinetics of solid-state nisoldipine under daylight and UV light illumination belongs to class of 
zero-order reaction  
 
10) Wonku kang24 et al has developed a simple and rapid quantification method for determining 
nisoldipine in plasma by Liquid Chromatography–Tandem Mass Spectrometry. After a simple 
protein precipitation with a mixture of 10% of zinc sulfate and methanol, the analytes were 
chromatographed on a reversed-phaseC18 column, and detected by MS/MS. The assay precision 
was less than 10.7%, and the accuracy ranged from 86 to112%. The limit of quantification was 
0.1 ng/ml. This method was used to measure the plasma concentration of nisoldipine from 
healthy subjects after a single 5-mg oral dose of nisoldipine. 
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Substructures 
• Dihydropyridines 
• Carboxylic Acids and Derivatives 
• Nitrobenzene’s 
• Acetates 
• Oxoazaniums 
• Ethers 
• Benzene and Derivatives 
• Nitro compounds 
• Enamines 
• Heterocyclic compounds 
• Aromatic compounds 
• Anilines 
Protein Binding    :       99% 
T1/2                                     :     7-12 hours 
 Dose                  :         34 mg of Nisoldipine for once-a-day oral  
                                                            Administration 
CLINICAL PHARMACOLOGY: 
 Mechanism of Action 
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering 
with the release of calcium from the sarcoplasmic reticulum, Nisoldipine inhibits the 
influx of extracellular calcium across the myocardial and vascular smooth muscle cell 
membranes The decrease in intracellular calcium inhibits the contractile processes of the 
myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, 
increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, 
decreased systemic blood pressure, and decreased after load.  
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Absorption and Distribution 
Relatively well absorbed into the systemic circulation with 87% of the radio labeled drug 
recovered in urine and feces. The absolute bioavailability of Nisoldipine is about 5%. 
Metabolism 
Pre-systemic metabolism in the gut wall, and this metabolism decreases from the 
proximal to the distal parts of the intestine. Nisoldipine is highly metabolized; 5 major 
urinary metabolites have been identified. The major biotransformation pathway appears 
to be the hydroxylation of the isobutyl ester. A hydroxylated derivative of the side chain, 
present in plasma at concentrations approximately equal to the parent compound, appears 
to be the only active metabolite and has about 10% of the activity of the parent 
compound. Cytochrome P450 enzymes are believed to play a major role in the 
metabolism of Nisoldipine. The particular isoenzyme system responsible for its 
metabolism has not been identified, but other Dihydropyridines are metabolized by 
Cytochrome P450 IIIA4 
.Elimination 
Although 60-80% of an oral dose undergoes urinary excretion, only traces of unchanged 
Nisoldipine are found in urine. 87% of the radio labeled drug is recovered in urine and 
feces. Nisoldipine is eliminated 60% to 80% in urine (traces unchanged), 5 urinary 
metabolites and only 1 active 
Pharmacodinamic 
Nisoldipine, a Dihydropyridines calcium-channel blocker, is used alone or with an 
angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina 
pectoris, and Prinzmetal's variant angina. Nisoldipine is similar to other peripheral 
vasodilators. Nisoldipine inhibits the influx of extra cellular calcium across the 
myocardial and vascular smooth muscle cell membranes possibly by deforming the 
channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of 
calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits 
the contractile processes of the myocardial smooth muscle cells, causing dilation of the 
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coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, 
decreased total peripheral resistance, decreased systemic blood pressure, and decreased 
after load. 
Elderly 
Higher Nisoldipine plasma concentrations (C max and AUC) have been found in elderly. 
Indications and Usage 
Treatment of hypertension, alone or in combination with other antihypertensive agents. 
Contraindications 
Sensitivity to Dihydropyridines calcium channel blockers. 
Dosage and Administration 
Adults 
PO Initiate therapy with 17 mg once daily, then increase by 8.5 mg/wk, or with longer 
intervals, to attain adequate BP control (max, 34 mg/day). 
Patients older than 65 yr of age, or patients with impaired liver function 
Initiate therapy with 8.5 mg once daily. 
General Advice 
• Have patient swallow tablets whole. Do not allow patient to crush, chew, or 
divide. 
• Administer once daily 1 h before or 2 h after a meal. Do not administer with a 
high-fat meal. Avoid grapefruit products. 
Storage/Stability 
Store at 68° to 77°F. Protect from light and moisture. 
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4. OBJECTIVE AND PLAN OF WORK 
4.1 OBJECTIVE 
 Among the various drugs currently available for the treatment of systematic 
hypertension, the calcium channel antagonists (CCAs) continue to receive much attention 
as a result of their benefits in the prevention of cardiovascular events and other 
complications. Nisoldipine as a new dihydropyridinecalcium ion antagonist. 
 Nisoldipine is chemically described as 3-isobutyl-5-methyl-1, 4-dihydro-2, 6-dimethyl-
4-(2-nitro phenyl)-pyridine-3, 5-dicarboxylate, is a calcium-channel-blocking 1, 4-
dihydropyridine derivative, with no identical ester functions, which has been developed 
as an antihypertensive and antianginaldrug.  
A Stability indicating methods is a quantitative analytical procedure used to detect a 
decrease in the amount of the active pharmaceutical ingredient (API) present due to 
degradation. According to FDA guidelines, a Stability indicating methods is defined as a 
validated analytical procedure that accurately and precisely measures active ingredients 
(drug substance or drug product) free from potential interferences like degradation 
products, process impurities, excipients, or other potential impurities, and the FDA 
recommends that all assay procedures for stability studies be stability indicating .During 
stability studies, liquid chromatography (LC) is used routinely to separate and quantitate 
the analyte of interest. 
 Stability indicating methods are quantitative test methods that can detect changes with 
time of drug substances and drug products. Information of type and amount of 
degradation products over time is important for safety of drugs. Therefore, FDA and 
other agencies but also good business practice requires such methods to be well designed 
and validated. 
Dissolution test has emerged in the pharmaceutical field as a very important tool based on 
the fact that for a drug to be absorbed and available to the systemic circulation, it must 
previously be solubilized. Therefore the dissolution studies are used not only to assess 
batch-to- batch consistency of drug release from solid dosage forms, but they are also 
essential in several stages of formulation development  .The initial assay parameters may  
determined with drug substance dissolved in a dissolution medium. At the present time 
there is no dissolution test has been described in literature for this drug.    
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Method validation is an essential step in drug analysis. The process confirms that the 
analytical procedure employed for the analysis is suitable for its intended use and shows 
reliability of the results produced by any method.         
The principal aspects of drug products that play an important role in shelf life 
determination of tablet formulation are assay and dissolution of active drug and 
degradants generated during the stability study. The assay of drug product in stability 
test sample needs to be determined using stability indicating method, as recommended by 
the International Conference on Harmonization (ICH) guidelines (ICH, 2000) and USP 
29(United State Pharmacopoeia, 2005).  
A thorough literature survey has revealed that  only few analytical Methods that have 
been developed for its determination of Nisoldipine in human plasma has been Mainly 
determined using liquid or gas chromatography with mass spectrometry, following a 
Liquid–liquid extraction. And it  has been analyzed for crystal structure Elucidation, and 
determination in formulations by voltametry, polarography.But there is no method has 
been developed for quantification for its formulation by High performance liquid 
chromatography. At the present time there is no dissolution test has been described in 
literature for this drug.    
The main purpose of this investigation is to develop and validate simple, precise, 
sensitive and accurate stability indicating reversed phase high-performance liquid 
chromatographic method for assay and validate a sensitive RP-HPLC method to be 
applied to the in vitro dissolution studies.  
 Therefore, the present study has been undertaken in order to develop a new, simple,  
reproducible validatable, transferable, robust, reliable, accurate and precise individual 
methodology for the Assay and Dissolution of Nisoldipine in pharmaceutical dosage 
forms by using HPLC(Reverse phase).  
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4.2 PLAN OF WORK 
4.2.1 ASSAY METHOD DEVELOPMEMT 
An attempt was made in a stepwise manner to develop a simple, rapid, selective and 
sophisticated Assay method, by High performance liquid chromatography (Reverse 
phase) for the Nisoldipine.  
The following stepwise protocol was followed. 
• As a start up, literature survey was done and from the literature survey 
chemical profile like solubility, chemical structure, pKa value and analytical 
profile were obtained. 
• From the data obtained, UV spectroscopic study was tried in the first place. 
• Later several trials were done in RP-HPLC using a different combination of 
mobile phases and finally optimized. 
• After optimization of the HPLC method, validation of the analytical method 
for the developed RP-HPLC method was done in accordance with the ICH 
guidelines. 
 
• The plan of work is presented in the following scheme 
  
 
 
 
 
 
 
 
 
 
 
Review of Literature 
Establishment of detection wavelength 
 
HPLC Trials with different combination 
of mobile phases and columns 
Optimization of the HPLC method 
Method validation for the above 
developed HPLC method as per ICH 
industrial guidelines 
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4.2.2 DISSOLUTION METHOD DEVELOPMENT 
An attempt was made in a stepwise manner to develop a simple, rapid, selective and 
sophisticated Analytical method &Dissolution method, by High performance liquid 
chromatography (Reverse phase) for the Nisoldipine 
 
The following stepwise protocol was followed. 
 
• Various trail was made to find out the solubility of drug in Water,0.1N HCL, PH  
6.8 Phosphate Buffer , and finally selected the suitable medium 
 
• Later several trials were done in RP-HPLC using a different combination of mobile 
phases and finally method was optimized. 
 
• Various trails ware made to find out to fixing dissolution  parameters like   
   RPM, Apparatus, Dissolution volume. 
 
• Dissolution method has been optimized by using similarity factor. 
 
• After optimization of the HPLC method, validation of the analytical method for the 
developed RP-HPLC method was done in accordance with the ICH guidelines. 
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• The plan of work is presented in the following scheme 
  
 
 
 
 
 
 
 
 
 
 
  
 
Solubility studies with different medium 
like PH 1.2 HCL+0.5%SLS, PH 
4.5+0.5%SLS, PH 6.8 PHOSPHATE 
PUFFER+0.5%SLS
HPLC Trials with different combination 
of mobile phases and columns 
Optimization of the HPLC method 
Method validation for the above 
developed HPLC method as per ICH 
industrial guidelines 
Dissolution trails with different RPM  
Dissolution Profile has optimized by 
using similarity factor  
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5. EXPERIMENTAL PART 
ASSAY METHOD DEVELOPMENT 
                       The need to save method development time and improve accuracy is 
forcing today’s analytical chemists to look for better, faster ways to develop stability 
indicating methods. 
                                   Starting with HPLC columns that offer excellent reproducibility, 
column lifetime and sensitivity this step by step protocol can save the method 
development chemists time and money required to establish new method. This approach 
is consistent with developing process. 
STEPS IN ASSAY METHOD DEVELOPMENT 
1. Selection of  Detector Wavelength 
2. Selection and Optimization of  Mobile Phase 
¾ pH of the buffer or pH of the Mobile Phase 
¾ Optimization of  Mobile Phase Composition 
3.  Selection of Column 
4. Selection of Flow Rate 
5. Selection of  Column Temperature 
6. Selection of  Diluent 
7. Selection of  Injection Volume 
8. Establishment of  System Suitability 
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5.1 ASSAY METHOD DEVELOPMENT 
DETECTION METHOD AND SELECTION OF WAVELENGTH 
Known concentrations of Nisoldipine working standard was taken and dissolved in 
Methanol such that the standard solution contains about 51 ppm.  Placebo & blank 
solutions also prepared. All these solutions were scanned between 200-400 nm using UV 
visible spectrophotometer. 
OPTIMIZATION OF MOBILE PHASE 
MOBILE PHASE COMPOSITION 
Trail: 1 
Preparation of mobile phase 
                                                  Accurately measured a volume of 1000ml of Acetonitrile 
(100%).Filtered and degassed for 2 mins. 
 
Diluent: pH 3 buffer: Methanol (50:50) 
 
Chromatographic conditions 
             Column   :  Peerless Basic C18 100 × 4.6 mm, 1.8µ  
             Flow rate   :  1.0ml/min  
             Column oven temperature  :  300c 
             Injection volume   :  20µl 
             Runtime   : 10 mins 
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Trail: 2 
Buffer Preparation: 
                           Weighed and dissolved about 2.72 g of Potassium dihydrogen phosphate 
and 1.74 g of DiPotassium hydrogen phosphate in1000 mL of Milli Q water & mixed and 
sonicated for 10 minutes.  
 Preparation of mobile phase 
                         Accurately measured a volume of 400ml of pH 6.8 Phosphate buffer and 
mixed with600ml of Acetonitrile (40:60) .filtered and degassed for 2 mins. 
 
Diluent: pH 3 buffer: Methanol (50:50) 
 
Chromatographic conditions 
             Column   :  Peerless Basic C18 100 × 4.6 mm, 1.8µ  
             Flow rate   :  1.0ml/min  
             Column oven temperature  :  300c 
             Injection volume   :  20µl 
             Runtime   : 10 mins 
              
Trail: 3 
Buffer Preparation: 
                           Weighed and dissolved about 2.72 g of Potassium dihydrogen phosphate 
and 1.74 g of   DiPotassium hydrogen phosphate in1000 mL of Milli Q water & mixed 
and sonicated for 10 minutes.  
 
 Preparation of mobile phase 
                        Accurately measured a volume of 200ml of pH 6.8 Phosphate buffer, 
600ml of Acetonitrile and 200 ml of Methanol (20:60:20).filtered and degassed the 
solution  for 2 mins. 
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Diluent: PH 3 buffer: Methanol (50:50) 
 
Chromatographic conditions 
             Column   :  Peerless Basic C18 100 × 4.6 mm, 1.8µ  
             Flow rate   :  1.0ml/min  
             Column oven temperature  :  300c 
             Injection volume   :  20µl 
             Runtime   : 10 mins 
    
           
Trail: 4 
Buffer Preparation: 
                           Weighed and dissolved about 2.72 g of Potassium dihydrogen phosphate 
and 1.74 g of   DiPotassium hydrogen phosphate in1000 mL of Milli Q water & mixed 
and sonicated for 10 minutes.  
  
 Preparation of mobile phase 
                           Accurately measured a volume of 250ml of pH 6.8 Phosphate buffer, 
500ml of Acetonitrile and 250 ml of Methanol (25:50:25).filtered and degassed the 
solution  for 2 mins. 
 
Diluent: PH 3 buffer: Methanol (50:50) 
 
Chromatographic conditions 
             Column   :  Peerless Basic C18 100 × 4.6 mm, 1.8µ  
             Flow rate   :  1.0ml/min  
             Column oven temperature  :  300c 
             Injection volume   :  20µl 
             Runtime   : 10 mins 
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Trail: 5 
Buffer Preparation: 
                           Weighed and dissolved about 2.72 g of Potassium dihydrogen phosphate 
and 1.74 g of   DiPotassium hydrogen phosphate in1000 mL of Milli Q water & mixed 
and sonicated for 10 minutes.  
 Preparation of mobile phase 
Accurately measured a volume of 300ml of pH 6.8 Phosphate buffer, 400ml of 
Acetonitrile and 300 ml of Methanol (30:60:30).filtered and degassed the solution  for 2 
mins. 
 
Diluent: PH 3 buffer: Methanol (50:50) 
 
Chromatographic conditions 
             Column   :  Peerless Basic C18 100 × 4.6 mm, 1.8µ  
             Flow rate   :  1.0ml/min  
             Column oven temperature  :  300c 
             Injection volume   :  20µl 
             Runtime   : 10 mins 
              
 
 
 
 
 
. 
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SOLUTION PREPARATION 
Preparation of 0.02M Phosphate buffer (pH 6.8) 
Weighed and dissolved about 2.72 g of Potassium dihydrogen phosphate and 1.74 g of 
DiPotassium hydrogen phosphate in1000 mL of Milli Q water & mixed well.  
Preparation of mobile phase 
Mixed pH 6.8 Phosphate buffer: methanol: acetonitrile in the ratio 30:30:40(v/v) filtered 
and degassed for 10 mins. 
Preparation of diluent  
Preparation of pH3 buffer 
Weighed and dissolved about 2.72 g of Potassium dihydrogen phosphate and 1.74 g of 
DiPotassium hydrogen phosphate in1000 mL of Milli Q water & mixed well.  
and pH was adjusted with ortho phosphoric acid. 
Mixed Methanol and pH3buffer in the ratio of 50:50(v/v) respectively  
Preparation of standard stock solution 
Accurately weighed and transferred about 51 mg of Nisoldipine working standard into 
100 mL volumetric flask, add about 40 ml MeOH, sonicated to dissolve the material 
completely, and add 20ml of acetonitrile and dilute to volume with MeOH and mixed. 
Preparation of standard solution 
Pipette 5 mL of above standard stock solution into a 50 mL volumetric flask dilute to 
volume with Diluents and mixed. 
Test preparation 
Weighed and transferred 5 tablets into a 100 ML volumetric flask added about 70 ML of 
diluent, sonicated for about 30 minutes with intermediate shaking, dilute to volume with 
diluent and mixed. The above solution was centrifuged for 10 min in centrifuge tubes at 
2500 RPM; 3mL of the centrifuged sample solution was diluted to 50mL with diluent and 
used as the test preparation 
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5.2 VALIDATION OF ASSAY METHOD 
 
VALIDATION APPROACH 
 Validation of analytical method was done to establish by laboratory studies, that 
the performance characteristics of the method meet the requirement for intended 
analytical application. 
 The following experimental design is drawn in order to prove the test method is 
capable to yield consistent, reliable and reproducible results within the predetermined 
acceptance limits 
¾ Acceptance criteria for above validation parameters are specified in individual 
experimental design  
¾ Observation and results are recorded in individual method validation data sheets. 
¾ Summarize the finding of the method validation and draw interference 
¾ Based on the interpretation of the results in method validation, draw the 
conclusion  
VALIDATION PARAMETERS 
 The following parameters have been validated  
¾ System suitability 
¾ Precision 
¾ Specificity 
¾ Linearity 
¾ Accuracy 
¾ Robustness 
¾ Ruggedness 
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VALIDATION PROCEDURES 
1) SYSTEM SUITABILITY 
      The standard solution was prepared by using Nisoldipine working standard as per 
test method and was injected ten replicate injections into the HPLC system. 
The system suitability parameters were evaluated from standard chromatograms by 
calculating the percentage RSD from ten replicate injections for Nisoldipine retention 
time and peak areas. 
 
2) PRECISION: 
 The precision of an analytical method is the closeness of agreement (Degree of 
scattered) between series of measurements obtained from multiple samplings of the same 
homogeneous sample under the prescribed conditions 
a) Repeatability (Method Precision) 
Repeatability expresses the precision under the same operating condition over a 
short interval of time. 
Procedure 
 Prepare and analysis six replicate sample preparations as per test method.  
Calculated individual assay value, mean assay value, %RSD and recorded. 
 
3) SPECIFICITY: 
 Specificity of analytical method is ability to measure specifically the analyte of 
interest without interference from blank and placebo. 
a) Check for interference from placebo: 
Placebo Preparation: 
 Weigh placebo equivalent to five intact tablets in 100ml volumetric flask, add 20ml of 
Acetonitrile and 50 ml of methanol and sonicated for some time, and make up the volume 
with methanol, take 3ml from above solution and makeup to 100ml with diluent. Inject 
the placebo preparation and check the interference  
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b) Check for interference from forced degradation studies: 
           Subjected the Nisoldipine tablets in following condition 
1. Acid Degradation 
2. Base Degradation 
3. Oxidative Degradation 
4. Hydrolysis Degradation 
5. Photolytic Degradation 
Ensure that at least one condition degradation is between 1 to 30% for each 
condition prepare blank accordingly 
 
1.1 Acid Degradation: 
   Weigh accurately transfer five tablets into 100ml volumetric flask, add 
25ml of 0.1N Hcl and sonicated with shaking to disappear the tablet completely and 
place in to water bath at 700C about 30 minutes. Add 25ml of 0.1NaoH for 
neutralization. Make up the volume 10ml of acetonitrile and 40ml of Methanol. From 
this pipette out 3ml and make up to 100ml with diluent. 
 
1.2 Base Degradation 
            Weigh accurately transfer five tablets into 100ml volumetric flask, add 25ml of 
0.1N Sodium Hydroxide and sonicated with shaking to disappear the tablet completely 
and place in to water Bath at 700C about30 minutes. Add 25ml of 0.1Hcl for 
neutralization. Make up the volume 10ml of acetonitrile and 40ml of Methanol. From this 
pipette out 3ml and make up to 100ml with diluent. 
 
1.3 Oxidative Degradation 
            Weigh accurately transfer five tablets into 100ml volumetric flask, 25ml of 2% of 
Hydrogen peroxide solution and for suitable interval, place in to water Bath at 400C about 
30 minutes and make up the volume with 10ml of acetonitrile and 40ml of Methanol. 
From this pipette out 3ml and make up to 100ml with diluent. 
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1.4 Hydrolytic Degradation 
                  Weigh accurately transfer five tablets into 100ml volumetric flask, add 
25ml of Water  and place the volumetric flask in water bath about 30 mints make up the 
volume with 10ml of acetonitrile and 40ml of Methanol .From this pipette out 3ml and 
make up to 100ml with diluent. 
 
1.5 Photolytic Degradation 
           Tablet powder (covered with aluminum foil) wash exposure in photo 
stability chamber as per guidelines and over all illumination of NLT-1.2 million lux hour 
and an integrated near UV energy of NLT- 200 watt hour/Sq.m. 
             Weigh accurately five tablets and crush them into powder. Tablet powder 
of 3900mg of exposed samples was transfer into 100ml volumetric flask add 20ml of 
Acetonitrile and 50ml of methanol and sonicated for some time and make up the volume 
with methanol, from this further dilute 3ml to 100ml with diluent 
Procedure: 
 Prepare standard and sample solution by suitable degradation method and injected 
into HPLC system and evaluate the peak purity. 
 
4) LINEARITY: 
 The linearity of analytical method is its ability to elicit test results that are 
directly, of by well defined mathematical transformation, proportional to the 
concentration of analyte in simple within a given working range 
Procedure: 
  A series of solutions are prepared using Nisoldipine working standard at 
concentration levels from 25% to 150% of target concentrations (25%, 50%, 75%, 100%, 
125%, 150%) measure the peak area response of the solutions 
 
 
 
 
EXPERIMENTAL PART-ASSAY 
 
   52 
 
5) ACCURACY (RECOVERY) 
 The accuracy of analytical method is the closeness of sample results obtained by 
that method to the true value. The true value is that result which would be observed in the 
absence of error. Accuracy may often be expressed as present recovery by assay of 
known, added amounts of analyte. Accuracy is a measure of the exactness of the 
analytical method that is true for all practical purpose. 
 Determine accuracy over the range 25%, 50%, 75%, 100%, 125% & 150% of the 
working concentration. Added calculated amount of Nisoldipine working standard or API 
ion placebo to attain 25%, 50%, 75%, 100%, 125% & 150%. 
RECOVERY PREPARATIONS: 
Level 1: (25%) 
  Weighed and transfer above 42.5mg of Nisoldipine into 100ml Volumetric 
flask, add 3780 mg of placebo add 20ml Acetonitrile and 80ml of Methanol and shake 
well and sonicate for some times. Pipette out 3ml of above solution and makeup the 
volume 100ml with diluent. 
Level 2: (50%) 
  Weighed and transfer above 85mg of Nisoldipine into 100ml Volumetric 
flask, add 3780 mg of placebo add 20ml Acetonitrile and 80ml of Methanol and shake 
well and sonicate for some times. Pipette out 3ml of above solution and makeup the 
volume 100ml with diluent. 
Level 3: (75%) 
  Weighed and transfer above 127.5mg of Nisoldipine into 100ml 
Volumetric flask, add 3780 mg of placebo add 20ml Acetonitrile and 80ml of Methanol 
and shake well and sonicate for some times. Pipette out 3ml of above solution and 
makeup the volume 100ml with diluent. 
Level 4: (100%) 
  Weighed and transfer above 170mg of Nisoldipine into 100ml Volumetric 
flask, add 3780 mg of placebo add 20ml Acetonitrile and 80ml of Methanol and shake 
well and sonicate for some times. Pipette out 3ml of above solution and makeup the 
volume 100ml with diluent. 
Level 5: (125%) 
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  Weighed and transfer above 212.5mg of Nisoldipine into 100ml 
Volumetric flask, add 3780 mg of placebo add 20ml Acetonitrile and 80ml of Methanol 
and shake well and sonicate for some times. Pipette out 3ml of above solution and 
makeup the volume 100ml with diluent. 
Level 6: (150%) 
  Weighed and transfer above 255mg of Nisoldipine into 100ml Volumetric 
flask, add 3780 mg of placebo add 20ml Acetonitrile and 80ml of Methanol and shake 
well and sonicate for some times. Pipette out 3ml of above solution and makeup the 
volume 100ml with diluent. 
Procedure: 
 Prepare three preparations for each level and injected each preparation in 
triplicate. Calculate the amount found and percentage recovery at each level and calculate 
the mean percentage recovery and %RSD 
 
6) ROBUSTNESS: 
a) Effect of variation in mobile phase composition: 
  A study was conducted to determine the effect of variation in organic 
phase composition in mobile phase. Standard solution prepared as per the test method 
was injected into HPLC system using various mobile phase compositions. The system 
suitability parameters were evaluated and found to be within the limits. 
b) Effect of variation of flow rate: 
 A study was conducted to determine the effect of variation in flow rate. Standard 
solution prepared as per the test method was injected into HPLC system using flow rate 
0.9ml/min and 1.1ml/min. The system suitability parameters were evaluated and found to 
be within the limits for 0.9ml/min and 1.1ml/min flow.  
Nisoldipine were resolved from all other peaks and the retention was compared 
with those obtained for mobile phase having flow rate 1.0ml/min.  
 
c) Effect of variation in pH: 
 A study was conducted to determine the effect of variation in PH. Standard 
solution prepared as per the test method was injected into HPLC system using 6.6 and 7. 
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The System suitability parameters were evaluated and found to be within the limits for 
pH 6.6 and 7.Nisoldipine were resolved from all other peaks and retention time were 
comparable with those obtained for mobile phase having pH 6.8 
 
d) Effect of variation in Temperature: 
 A study was conducted to determine the effect of variation in Temperature. 
Standard solution prepared as per the test method was injected into HPLC system at 
28oC&320C temperature. Similarly sample solution was chromatographed at 30oC 
temperature. Nisoldipine were resolved from all other peaks and retention times were 
comparable with those obtained mobile phase having 30oC temperature. 
e) Filter validation 
            To demonstrate robustness of assay method, carry out filter validation using two 
different filters prepare test solution in triplicate. Centrifuge and filter different portions 
of the test preparation and inject into the HPLC system along with unfiltered standard. 
Calculate the percentage assay. 
 
7) RUGGEDNESS: 
 Intermediate Precision within laboratory precision on a different day, by a 
different analyst, by different column by using same lot of sample as specified under 
repeatability. Bench top stability of mobile phase, standard and sample preparation also 
evaluated. 
Procedure: 
 Repeated the procedure followed for method precision on a different day, 
different analyst, using different HPLC system and by different column by using same lot 
of sample calculate individual assay value mean assay value, %RSD, overall %RSD. 
Find out the difference in the assay value of intermediate precision. 
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5.3 DISSOLUTION 
DETECTION METHOD AND SELECTION OF WAVELENGTH 
Known concentrations of Nisoldipine working standard was taken and dissolved in Methanol 
such that the standard solution contains about 51 ppm.  Placebo & blank solutions also prepared. 
All these solutions were scanned between 200-400 nm using UV visible spectrophotometer. 
OPTIMIZATION OF MOBILE PHASE 
MOBILE PHASE COMPOSITION 
Trail: 1 
Buffer Preparation: 
                           Weighed and dissolved about 2.72 g of Potassium dihydrogen phosphate and 
1.74 g of DiPotassium hydrogen phosphate in1000 mL of Milli Q water & mixed and sonicated 
for 10 minutes.  
 Preparation of mobile phase 
                         Accurately measured a volume of 300 ml of pH 6.8 Phosphate buffer and mixed 
with400ml of Acetonitrile 300ml of methanol (30:40:30) .filtered and degassed for 2 mins. 
Diluent: dissolution medium 
Chromatographic conditions 
             Column    :  Prontosil H C18 100 × 4.6 mm, 3µ  
             Flow rate    :  1.5ml/min  
             Column oven temperature   :  Ambient 
             Injection volume    :  50µl 
             Runtime    : 10 mins 
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Trail: 2 
Buffer Preparation: 
Preparation of pH 3.0 buffer 
7ml of triethylamine is mixed with 1000ml of water and ph was adjusted with ortho phosphoric 
acid.  
 Preparation of mobile phase 
                         Accurately measured a volume of 400ml of pH 3 Phosphate buffer and mixed 
with600ml of Acetonitrile (40:60) .filtered and degassed for 2 mins. 
Diluent: dissolution medium 
Chromatographic conditions 
             Column    :  Prontosil H C18 100 × 4.6 mm, 3µ  
             Flow rate    :  1.5ml/min  
             Column oven temperature   :  Ambient 
             Injection volume    :  50µl 
             Runtime    : 10 mins 
 
Trail: 3 
Buffer Preparation: 
Preparation of pH 3.0 buffer 
7ml of triethylamine is mixed with 1000ml of water and ph was adjusted with ortho phosphoric 
acid.  
Preparation of mobile phase 
            Accurately measured a volume of 200ml of pH 3 Phosphate buffer and mixed with600ml 
of Acetonitrile ,200ml of Methanol in the ratio of(20:60:20) .filtered and degassed for 2 mins. 
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Diluent: dissolution medium 
Chromatographic conditions 
             Column    :  Prontosil H C18 100 × 4.6 mm, 3µ  
             Flow rate    :  1.5ml/min  
             Column oven temperature   :  Ambient 
             Injection volume    :  50µl 
             Runtime    : 10 mins 
Trail: 4 
Buffer Preparation: 
Preparation of pH 3.0 buffer 
7ml of triethylamine is mixed with 1000ml of water and ph was adjusted with ortho phosphoric 
acid.  
 Preparation of mobile phase 
                         Accurately measured a volume of 300ml of pH 3 Phosphate buffer and mixed 
with400ml of Acetonitrile,300 ml of Methanol in the ratio of (30:40:30) .filtered and degassed 
for 2 mins. 
Diluent: dissolution medium 
Chromatographic conditions 
             Column    :  Prontosil H C18 100 × 4.6 mm, 3µ  
             Flow rate    :  1.5ml/min  
             Column oven temperature   :  Ambient 
             Injection volume    :  50µl 
             Runtime    : 10 min 
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Solubility studies  
 Solubility of the drug can studied in different medium like water, 0.1HCL, pH4.5 
Phosphate buffer, pH 6.8 Phosphate buffer. 
Selection of dissolution parameters. 
Dissolution parameters like Medium, Apparatus, RPM, Time points, Medium volume can 
be selected from Office of Generic Drugs. It can be optimized with different trails and using  
similarity factor. 
Preparation of solutions 
Preparation of pH 3.0 buffer 
Weighed and dissolved about 2.72 g of Potassium dihydrogen phosphate and 1.74 g of 
DiPotassium hydrogen phosphate in1000 mL of Milli Q water & mixed well. And pH was 
adjusted with ortho phosphoric acid. 
Preparation of mobile phase 
Mixed pH3 buffer: methanol: Acetonitrile in the ratio 30:30:40(v/v) filtered and degassed for 10 
mins. 
Preparation of standard stock solution 
Accurately weighed and transferred about 50 mg of Nisoldipine working standard into 100 ML 
volumetric flask, add about 70ml of methanol, sonicated to dissolve the material completely, 
dilute to volume with methanol and mixed. 
Preparation of standard solution 
Pipette 4 mL of above standard stock solution into a 50ml volumetric flask dilute to volume with 
dissolution medium (0.1NHCL+0.5%SLS) and mixed. 
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Test preparation 
Weighed and transferred each individual tablet to respective dissolution vessels containing 
900ML of dissolution medium (0.1NHCL+0.5%SLS), and started the run. The samples are 
collected at specific time point. 
5.4 VALIDATION OF DISSOLUTION METHOD 
VALIDATION APPROACH 
 Validation of analytical method was done to establish by laboratory studies, that the 
performance characteristics of the method meet the requirement for intended analytical 
application. 
 The following experimental design is drawn in order to prove the test method is capable 
to yield consistent, reliable and reproducible results within the predetermined acceptance limits 
¾ Acceptance criteria for above validation parameters are specified in individual 
experimental design  
¾ Observation and results are recorded in individual method validation data sheets. 
¾ Summarize the finding of the method validation and draw interference 
¾ Based on the interpretation of the results in method validation, draw the conclusion  
VALIDATION PARAMETERS 
 The following parameters have been validated  
¾ System suitability 
¾ Precision 
¾ Specificity 
¾ Linearity 
¾ Accuracy 
¾ Robustness 
¾ Ruggedness 
¾ Sink condition 
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VALIDATION PROCEDURES 
1) SYSTEM SUITABILITY 
      The standard solution was prepared by using Nisoldipine working standard as per test 
method and was injected ten times into the HPLC system .The system suitability parameters 
were evaluated from standard chromatograms by calculating the percentage RSD from ten 
replicate injections for Nisoldipine retention time and peak areas. 
2) PRECISION: 
 The precision of an analytical method is the closeness of agreement (Degree of scattered) 
between series of measurements obtained from multiple samplings of the same homogeneous 
sample under the prescribed conditions 
A) Repeatability (Method Precision) 
Repeatability expresses the precision under the same operating condition over a short 
interval of time. 
Procedure 
 Prepare and analysis six replicate sample preparations as per method. Calculated individual 
%Dissolution value, %RSD and 95% confidence interval and recorded. 
3) SPECIFICITY: 
 Specificity of analytical method is ability to measure specifically the analyte of interest 
without interference from blank and placebo. 
a) Check for interference from placebo: 
Placebo Preparation: 
 Weigh placebo equivalent to one tablet, transfer in to dissolution vessel and add 900 ml of 
dissolution medium (0.1NHCL+0.5%SLS), and started the run. The samples are collected at 
specific time point.(24th hour).Inject the sample and check the interference  
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4) LINEARITY: 
 The linearity of analytical method is its ability to elicit test results that are directly, of by 
well defined mathematical transformation, proportional to the concentration of analyte in simple 
within a given working range 
Procedure: 
  A series of solutions are prepared using Nisoldipine working standard at concentration 
levels from 25% to 150% of target concentrations (25%, 50%, 75%, 100%, 125%, 150%) 
measure the peak area response of the solutions 
5) ACCURACY (RECOVERY) 
 The accuracy of analytical method is the closeness of sample results obtained by that 
method to the true value. The true value is that result which would be observed in the absence of 
error. Accuracy may often be expressed as present recovery by assay of known, added amounts 
of analyte. Accuracy is a measure of the exactness of the analytical method that is true for all 
practical purpose. 
 Determine accuracy over the range 25%, 50%, 75%, 100%, 125% & 150% of the 
working concentration. Added calculated amount of Nisoldipine working standard or API ion 
placebo to attain 25%, 50%, 75%, 100%, 125% & 150%. 
RECOVERY PREPARATIONS: 
Level 1: (25%) 
  Weighed and transfer about 8.5mg of Nisoldipine and add 756 mg of placebo, 
transfer in to dissolution vessel and add 900 ml of dissolution medium (0.1NHCL+0.5%SLS), 
and started the run. The samples are collected at specific time point (24th hour). 
 Level 2: (50%) 
  Weighed and transfer about 17mg of Nisoldipine and add 756 mg of placebo, 
transfer in to dissolution vessel and add 900 ml of dissolution medium (0.1NHCL+0.5%SLS), 
and started the run. The samples are collected at specific time point (24th hour). 
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Level 3: (75%) 
  Weighed and transfer about 25.5mg of Nisoldipine and add 756 mg of placebo, 
transfer in to dissolution vessel and add 900 ml of dissolution medium (0.1NHCL+0.5%SLS), 
and started the run. The samples are collected at specific time point (24th hour). 
Level 4: (100%) 
  Weighed and transfer about 34mg of Nisoldipine and add 756 mg of placebo, 
transfer in to dissolution vessel and add 900 ml of dissolution medium (0.1NHCL+0.5%SLS), 
and started the run. The samples are collected at specific time point (24th hour). 
Level 5: (125%) 
  Weighed and transfer about 42.5mg of Nisoldipine and add 756 mg of placebo, 
transfer in to dissolution vessel and add 900 ml of dissolution medium (0.1NHCL+0.5%SLS), 
and started the run. The samples are collected at specific time point (24th hour). 
Level 6: (150%) 
  Weighed and transfer about 51mg of Nisoldipine and add 756 mg of placebo, 
transfer in to dissolution vessel and add 900 ml of dissolution medium (0.1NHCL+0.5%SLS), 
and started the run. The samples are collected at specific time point (24th hour). 
Procedure: 
Prepare three preparations for each level and injected each preparation in triplicate. Calculate the 
amount found and percentage recovery at each level and calculate the mean percentage recovery 
and %RSD. 
6) ROBUSTNESS: 
a) Effect of variation of flow rate: 
 A study was conducted to determine the effect of variation in flow rate. Standard solution 
prepared as per the test method was injected into HPLC system using flow rate 1.4ml/min and 
1.6ml/min. The system suitability parameters were evaluated and found to be within the limits 
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for 1.4ml/min and 1.6ml/min flow. Nisoldipine were resolved from all other peaks and the 
retention was compared with those obtained for mobile phase having flow rate 1.5ml/min.  
b) Effect of variation in pH: 
 A study was conducted to determine the effect of variation in pH. Standard solution 
prepared as per the test method was injected into HPLC system using 2.8 and 3.2The System 
suitability parameters were evaluated and found to be within the limits for pH 2.8 and 3.2. 
Nisoldipine were resolved from all other peaks and retention time were comparable with those 
obtained for mobile phase having pH 3 
c) Filter validation 
To demonstrate robustness of dissolution method, carry out filter validation using two different 
filters. Prepare test solution in triplicate. Centrifuge and filter different portions of the test 
preparation and inject into the HPLC system along with unfiltered standard. Calculate the 
percentage dissolution. 
7) RUGGEDNESS: 
 Intermediate Precision within laboratory precision on a different day, by a different 
analyst, by different column by using same lot of sample as specified under repeatability. 
Procedure: 
 Repeated the procedure followed for method precision on a different day, different 
analyst, using different HPLC system and by different column by using same lot of sample 
calculate individual assay value mean assay value, %RSD, overall %RSD. 
Find out the difference in the assay value of intermediate precision. 
8) SINK CONDITION 
Perform dissolution on Nisoldipine drug substance in dissolution medium by adding 102mg of 
Nisoldipine to dissolution vessel at room temperature with 150 rpm. Calculate the % dissolution 
of Nisoldipine. 
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6 RESULTS AND DISSCUSION 
6.1 ASSAY 
Optimization of chromatographic conditions 
Suitable selection of the method depends upon the nature of the sample, its 
molecular weight and solubility. Hence the drugs selected in the present study polar in 
nature, RP-HPLC method was selected because of its simplicity. 
For the determination of wavelength for the estimation of Nisoldipine, UV 
spectrum was recorded in the range of 200-400 nm. After receiving the spectrum of 
standard, sample, placebo, wavelength of detection method was selected as 333nm. 
(Fig no 1.1-1.4) 
 
The optimization of HPLC parameters was done by investigating the influence 
of the mobile phase composition while stationary phase, detection wavelength, 
injection volume, flow rate  and column oven temperature were set constant.  
In the case of Trail 1 acetonitrile was selected as mobile phase but resulted in 
no elution of analyte. In the case of Trail 2 pH6.8 Phosphate buffer: acetonitrile was 
selected as mobile phase at a ratio of 50:50. Potassium phosphate buffer is selected 
basing on literature studies and it’s finalized. pH of the buffer can be selected based 
on the pKa value of the drug. Nisoldipine has 7.2 as a pKa. So the pH of the buffer 
can be fixed near to that pKa value. But resulted in poor tailing and poor peak shape 
(Figure2.1). Hence pH6.8 Phosphate buffer: Acetonitrile: methanol was selected as a 
mobile phase at a ratio of 20:60:20 and chromatograms were recorded in Trail 3. 
While using methanol in the mobile phase, peak shape was good. But the retention 
time was too short and theoretical plate count also very less (Figure 2.2). So in Trail 4 
and 5 the above mobile phase ratio was adjusted in to 25:50:25&30:40:30 
respectively. Finally in the Trail 5 the peaks with good symmetry, optimized retention 
time, tailing factor were observed (figure 2.3, 2.4) and therefore this was selected as 
the mobile phase condition for this method the column thermostat was maintained at 
30˚C. Initially injection column was stabilized with the initial mobile phase 
concentration for 60 min. 
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Many trials on composition of buffer and organic phase Results are as follows 
Table No 6.1.1 
Composition of 
Mobile phase. 
Retention 
Time 
Tailing 
factor 
Theoretical 
plates 
ACN - - - 
PH6.8 PHOSPHATE 
BUFFER:ACN 
40:60 
6.4 2.7 2906 
PH6.8 PHOSPHATE BUFFER: 
ACN:MeOH  
(20:60:20) 
2.6 1.6 6399 
PH6.8 PHOSPHATE BUFFER: 
ACN:MeOH 
(25:50:25) 
2.8 1.6 6773 
PH6.8 PHOSPHATE BUFFER: 
ACN:MeOH 
(30:40:30) 
5.2 1.5 12173 
 
 
SELECTION OF COLUMN 
Keeping the mobile phase ratio 30:40:30 pH 6.8 phosphate buffer: Acetonitrile: 
Methanol, the chromatograms were recorded with C18 Column (peerless Basic (100 
X 4.6mm) 1.8µm. At this column, the peaks were sharp. So this column was kept 
constant for the analysis (also tried with different particle size of stationary phase like 
5µ, 3µ.)3µ column also produce good peak symmetry and retention time. For the 
measurement of Peak purity we can go with 1.8 µ column. 
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Table 6.1.2 
 
 
 
 
 
 
 
 
 
 
 
EFFECT OF FLOW RATE: 
 Keeping the mobile phase ratio 30:40:30 pH 6.8 phosphate buffer: 
Acetonitrile: Methanol, the chromatograms were recorded at a flow rate of 1.0ml/min. 
At this flow rate, the peaks were sharp. So 1.0ml/min was kept constant for the 
analysis (flow rate 0.8ml/min 1.2ml/min, up to 1.5ml/min were also tried, but did not 
give any satisfactory results). 
Results Found Are As Follows 
 
Table 6.1.3 
Flow rate 
mL /min 
Retention 
time 
Tailing 
factor 
Theoretical 
Plates 
0.8 6.2 1.5 13365 
1.0 5.2 1.5 12190 
1.2 4.1 1.5 11373 
1.5 3.3 1.5 9890 
                                                                                                                         
 
 
 
 
Column 
Retention 
Time(min) 
Area 
Tailing 
factor 
Theoretical 
plates 
PRONTOSIL 
C18(150*4.6)5µ 
6.5 897275 1.3 7052 
NUCLEODUR 
C18(100*4.6)3µ 
4.5 896747 1.5 7506 
PEERLESS 
BasicC18(100*4.6) 
1.8 µ 
5.2 904747 1.5 12186 
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EFFECT OF COLUMN OVEN TEMPERATURE 
Keeping the mobile phase ratio 30:40:30 pH 6.8 phosphate buffer: Acetonitrile: 
Methanol, the chromatograms were recorded at an oven temperature at 300C. At this 
flow condition, the peaks were sharp. So 300C was kept constant for the analysis 
(column oven temperature ambient, 350C, 400C were also tried, but did not give any 
satisfactory results). 
Results Found Are As Follows 
 
Table 6.1.4 
Temp °C 
Retention 
time 
Tailing 
factor 
Theoretical 
plates 
ambient 5 1.6 12531 
30°c          5.2 1.5 12197 
350 C 4.6 1.5 11949 
40°c 4.3 1.4 11162 
 
ADJUSTING THE INJECTION VOLUME 
Keeping the mobile phase ratio 30:40:30 pH 6.8 phosphate buffer: Acetonitrile: 
Methanol, the chromatograms were recorded as injection volume 20. At this 
condition, the peaks were sharp. So 20 µL was kept constant for the analysis 
(injection volume 40 µL, 50 µL, 80 µL were also tried) 
Table 6.1.5 
Injection 
vol (µL) 
Retention 
Time 
Area 
Tailing 
Factor 
Theoretical 
Plates 
20 5.2 901396 1.5 12237 
40 4.9 1664761 1.5 12457 
50 5 2078280 1.6 12473 
80 5 3317006 1.6 12280 
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QUANTITATIVE DETERMINATION OF THE DRUG 
Preparation of pH 6.8 Phosphate buffer 
Weighed and dissolved about 2.72 g of Potassium dihydrogen phosphate and 1.74 g 
of DiPotassium hydrogen phosphate in1000 mL of Milli Q water & mixed well.  
Preparation of mobile phase 
Mixed pH 6.8 Phosphate buffer: methanol: acetonitrile in the ratio 30:30:40(v/v) 
filtered and degassed for 10 mins. 
Preparation of diluent  
Preparation of pH3 Phosphate buffer 
Weighed and dissolved about 2.72 g of Potassium dihydrogen phosphate and 1.74 g 
of DiPotassium hydrogen phosphate in1000 mL of Milli Q water & mixed well. And 
pH was adjusted with ortho phosphoric acid. 
Mixed Methanol and pH3buffer in the ratio of 50:50(v/v) respectively  
Preparation of standard stock solution 
Accurately weighed and transferred about 51 mg of Nisoldipine working standard into 
100 mL volumetric flask, add about 40 ml MeOH, sonicated to dissolve the material 
completely, and add 20ml of acetonitrile and dilute to volume with MeOH and mixed. 
Preparation of standard solution 
Pipette 5 mL of above standard stock solution into a 50 mL volumetric flask dilute to 
volume with Diluents and mixed. 
Test preparation 
Weighed and transferred 5 tablets into a 100 ML volumetric flask added about 70 ML 
of diluent, sonicated for about 30 minutes with intermediate shaking, dilute to volume 
with diluent and mixed. The above solution was centrifuged for 10 min in centrifuge 
tubes at 2500 RPM; 3mL of the centrifuged sample solution was diluted to 50mL with 
diluent and used as the test preparation 
Fixed Chromatographic system 
1. Liquid chromatograph equipped with a 333 nm UV detector. 
2. Column: 100 x 4.6 mm column that contains  1.8 µm packing of octadecyl 
silane chemically bonded to porous silica or ceramic micro particles [peerless 
Basic( 100 X 4.6mm )1.8µm ] 
3. Column temperature   : 30°c 
4. Flow rate    : 1.0 mL/min 
5. Injection volume   : 20 µl 
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6. Run time    :   9 min 
System Suitability 
Inject 20 µL portion of diluent (single injection) and standard solution (five replicate 
injections) into the chromatograph record the chromatograms and measure the 
responses for the major peak. 
The USP tailing factor for Nisoldipine peak should not be more than 2.0 
 
CALCULATION 
   
 
  Amount of Nisoldipine                                                   AxWsx5x100x100 x Px100 
            Present                                                        =           ────────────── 
      (% label claim)                                                Bx100x50xNx3 x Lx100  
  
 
 A=Peak area of Nisoldipine in test preparation. 
 B=Average peak area of Nisoldipine in standard preparation. 
 Ws=Weight of Nisoldipine working standard taken, in mg 
 P=Potency of Nisoldipine m working standard taken 
 L=Label claim of Nisoldipine in mg, per tablet 
 N=Number of tablet taken 
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6.2 METHOD VALIDATION- ASSAY 
SYSTEM SUITABILITY AND SYSTEM PRECISION 
1. SYSTEM PRECISION 
Inject ten replicate injections of Nisoldipine standard preparation into HPLC system 
and calculate relative deviation of Nisoldipine peak area. 
Table 6.2.1 
 
Injection no. Nisoldipine peak area 
1 932986 
2 933694 
3 933202 
4 932596 
5 932928 
6 933031 
7 932978 
8 932223 
9 933270 
10 933167 
Average 933007 
% RSD 0.15 
 
 
SYSTEM SUITABILITY 
Prepare system suitability solution as per the developed method and inject into HPLC 
system 
 Table 6.2.2 
System Suitability 
Parameters Observed value Acceptance limit 
Tailing 1.5 NMT 2.0 
plate count 11577 NLT 3500 
% RSD of Retention 
time 0.45 NMT 2.0% 
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Acceptance Criteria 
1) The % RSD for the peak area from ten replicate injections of Nisoldipine should 
be NMT 2% 
   2)   The %RSD for the retention time of Nisoldipine from ten replicate injection of 
       Standard Solution should not be more than 2% 
3)    The number of theoretical plates (N) for the Nisoldipine peak is NLT 3500 
4)    The Tailing factor (T) for the Nisoldipine peak is NMT 2.0 
Observation 
1)    The % RSD for the peak area from ten replicate injections of Nisoldipine is 0.15 
2)    The %RSD for the retention time of Nisoldipine from ten replicate injection of   
       Standard   Solution should 0.45 
3)   The number of theoretical plates (N) for the Nisoldipine peak is 11577 
4)   The Tailing factor (T) for the Nisoldipine peak is 1.5 
Conclusion  
It passes the system suitability 
 
 
2. SPECIFICITY 
PLACEBO INTERFERENCE 
Perform assay in triplicate on placebo with equivalent concentration to that of the test 
concentration in triplicate and evaluate the interference for each of the placebo 
preparations. 
Table 6.2.3 
 
 
 
 
 
 
Acceptance criteria 
No Interference from Placebo 
Conclusion  
% interference from placebo was found to be within the acceptance criteria 
Sample no. % interference 
1 0 
2 0 
3 0 
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INTERFERENCE FROM DEGRADANTS 
Table 6.2.4 
Sample name 
Purity angle Purity threshold 
Purity flag Drug 
substance 
Drug 
product 
Drug 
substance 
Drug 
product 
Unstressed 
 
0.107 
 
 
0.103 
 
0.273 0.239 No 
Stressed with 
0.1N HCL on 
a water bath 
at 70 °c for 30 
min 
0.067 0.095 0.236 0.238 No 
Stressed with 
0.1N NaOH 
on a water 
bath at 75 °c 
for 3hrs 
 
0.082 
 
 
0.065 
 
0.249 0.237 No 
Stressed with 
2% 
H2O2solution 
by keeping on 
bench top for 
30 min 
0.099 0.147 0.236 0.228 No 
Stressed with 
water  on 
water bath at 
75°c for 8 hrs 
 
0.091 
 
 
0.084 
 
0.238 0.237 No 
Stressed with 
UV for about 
54 hrs 
0.068 0.068 0.235 0.237 No 
Stressed with 
visible light 
for about 
288hrs 
 
0.070 
 
 
0.080 
 
0.226 0.232 No 
 
Acceptance criteria 
Purity angle should be less than purity threshold. 
Nisoldipine peaks should not have any flag in purity results table 
Conclusion 
% interference from degradants was found to be within the acceptance criteria 
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3. LINEARITY OF METHOD 
To demonstrate the linearity of assay method, inject in duplicate five standard 
solutions with concentration equivalent to 25 % to 150% target concentration of 
standard. Plot a graph to concentration versus average peak area. 
Table 6.2.5 
S. No. Conc (µg/mL) Average area 
1 12.75 231773 
2 25.5 460356 
3 38.25 699126 
4 51 925418 
5 63.75 1142144 
 
6 76.5 1390715 
Coefficient correlation       =         0.9998 
 
Chart No: 1 
 
 
Acceptance Criteria 
Coefficient of correlation shall be NLT 0.999    
y = 18089x + 867.1
R² = 0.999
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4. PRECISION 
Repeatability  
Determine the precision of the developed method by assaying six samples of 
homogenous blend prepared by mixing placebo and Nisoldipine raw material  
Table 6.2.6 
Test no Area Average area % Assay 
1 
934043 
933844 100.4 
933646 
2 
934420 
934496 100.5 
934572 
3 
932840 
932821 100.3 
932802 
4 
932447 
932786 100.3 
933026 
5 
931972 
931972 100.2 
931972 
6 
932084 
931972 100.3 
932374 
Average 
 
932982 
 
100.3 
% RSD 0.10 0.10 
 
     
Acceptance criteria 
1) The Average Assay should be not less than 95%. 
2) The relative standard deviation of assay should not be more than 2.0%. 
 
Observation  
1) The Average assay is 100.3 
2) The relative standard deviation of assay is 0.10 
Conclusion: The results obtained are well within the acceptance criteria. Therefore 
method is precise. 
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5. ACCURACY 
To validate, the assay method can accurately quantify Nisoldipine within the 
excipients, proportionally spiking various amounts of Nisoldipine raw material and 
the placebo at various concentrations ranging from 25 % to 150 %. 
Table 6.2.7 
 
Sample 
no 
Spike 
level % 
mg 
added 
mg found 
% 
recovery 
avg. % 
recovery 
% RSD 
 
1 
 
25 
 
8.5 
8.5 100 
99.6 0.7 8.5 100 
8.4 98.8 
 
2 
 
50 
17 
 
17 100 
99.6 0.7 16.8 98.8 
17 100 
 
3 
 
75 
25.5 
 
25.4 99.6 
99.7 
 
0.2 25.4 99.6 
25 100 
 
4 
 
100 
34 
34 100 
99.9 0.2 33.9 99.7 
34 100 
 
5 
 
125 
 
42.5 
42.5 100 
99.8 
 
0.3 42.5 100 
42.3 99.5 
 
 
6 
150 51 
50.9 99.8 
99.7 0.1 50.8 99.6 
50.9 99.8 
 
Acceptance Criteria 
 The average recovery of Nisoldipine at each spike level should not be less than 95% 
and not more than 105%. 
Conclusion  
The % recovery at each level is found to be within the limits. 
Hence the method is accurate in the specified range. 
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6. RUGGEDNESS 
a. Analyst to analyst variability 
To demonstrate intermediate precision of assay method, conduct analyst to analyst 
variability by two analysts. Analyst 2 shall perform precision of test method on 
different day preparing three samples of Nisoldipine tablet blend, prepared by mixing 
placebo and Nisoldipine raw material as per the composition.   
 
Table 6.2.8 
System suitability 
Observed values Acceptance 
criteria Analyst-1 Analyst-2 
Tailing factor 1.5 1.5 NMT 2 
plate count 11495 11483 NLT 3500 
 
 
Table 6.2.9 
Sample no 
Assay of Nisoldipine as % of labeled amount 
Analyst-1 Analyst-2 
1 100.3 99.7 
2 99.9 98.9 
3 100.2 100.2 
Average 100.1 99.6 
%RSD 0.20 0.70 
Over all % 
RSD 0.45 
 
Acceptance criteria 
The all individual assays of Nisoldipine should be within 95% to 105% 
Relative standard deviation of % assay results should not be more than 2.0% by both 
the analysts. 
The overall RSD for 12 values shall be NMT 2.0 %.  
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b. System to system variability 
To demonstrate the ruggedness of assay method, carryout system to system variability 
on two HPLC systems using same column under similar conditions. Assay three 
different preparations prepared by mixing Nisoldipine raw material and the placebo as 
per composition given in the formula. 
 
 
Table 6.2.10 
System suitability 
Observed values Acceptance 
criteria System- 1 (shimadzu) System- 2 (shimadzu) 
Tailing factor 1.5 1.5 NMT 2 
USP plate count 11496 11519 NLT 3500 
 
 
Table 6.2.11 
Sample no 
Assay of Nisoldipine as % of  labeled  amount 
System-1 System-2 
1 99.6 99.7 
2 99.4 99.6 
3 99.3 99.2 
Average 99.4 99.5 
%RSD 0.20 0.30 
Overall % RSD 0.25 
 
Acceptance criteria 
The all individual assays of Nisoldipine should be within 95% to 105%. 
Relative standard deviation of % assay results should not be more than 2.0% by both 
the analysts 
The overall RSD for 6 values shall be NMT 2.0 %.  
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c. Column to column variability 
To demonstrate the ruggedness of assay method, carryout column to column 
variability using the columns of the same manufacturer or different manufacturer on 
the same HPLC system under similar conditions. Assay three different preparations 
prepared by mixing Nisoldipine raw material and the placebo as per composition 
given in the formula                                  
 
Table 6.2.12 
System suitability 
Observed values Acceptance 
Criteria Column-1 
(Peerless) 
Column-2       
( Hypersil BDS)
Tailing factor 1.5 1.5 NMT 2 
USP plate count 11558 11603 NLT 3500 
 
 
Table 6.2.13 
Sample no. Assay of Nisoldipine as % of  labeled amount 
column-1 column-2 
1 99.6 99.9 
2 99.9 100.1 
3 100.2 100.3 
Average 99.9 
 
100.1 
 
%RSD 0.30 
 0.20 
Overall % RSD 0.25 
 
 
Acceptance criteria 
 
The all individual assays of Nisoldipine should be within 95% to 105%. 
Relative standard deviation of % assay results should not be more than 2.0% by both 
the columns. 
The overall RSD for 6 values shall be NMT 2.0 %. 
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 d. Bench top stability of mobile phase 
Prepare the mobile phase as per the developed method and keep it on bench top with 
well closed condition. Prepare the system suitability solution, standard solution and 
test solutions prepared by mixing placebo and Nisoldipine raw material as per 
formula. Inject the system suitability solutions, standard solutions and the test 
solutions at initial, 1 day and 2 days. Evaluate the system suitability parameters and % 
assay.                                                
Table 6.2.14 
System 
suitability 
parameters 
Observed values Acceptance 
criteria Initial 1 day 2 day 
Tailing factor 1.5 1.5 1.5 NMT 2.0 
USP plate count 11594 11523 11454 NLT 3500 
 
 
Table 6.2.15 
Approx. time in days % assay Difference from initial 
Initial 100 NA 
1 day 99.3 0.7 
2 day 99.3 0.7 
 
Acceptance criteria 
The % assay result should not differ from initial value by more than 2.0%. 
All system suitability parameters shall meet the requirements. 
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e. Bench top stability of test & standard preparations of Nisoldipine  
Perform the assay of Nisoldipine tablets prepared by mixing placebo and Nisoldipine 
as per the formula and prepare the test in duplicate on tablets. Keep the standard, test 
preparations on bench top, and analyse at 1-day intervals up to 2-days against a 
freshly prepared standard each time. 
Table 6.2.16 
Time in 
days 
% assay of 
Std 
preparation 
Difference
% assay of test     
preparation 
Difference 
Test-1 Test-2 Test-1 Test-2 
Initial 100 NA 99.5 99.7 NA NA 
Day 1 99.8 0.2 99.5 99.3 0.0 0.4 
Day 2 98.9 1.3 98.5 98.8 1.0 1.1 
 
Acceptance criteria 
The % assay of Nisoldipine in standard and test preparation should not differ by more 
than 2.0 % from initial value. 
f. Refrigerator stability of Nisoldipine std & test preparations 
Perform the assay of Nisoldipine tablets prepared by mixing placebo and Nisoldipine 
as per the formula and prepare the test in duplicate on tablets. Keep the standard, test 
preparations in refrigerator, and analyse at 1-day intervals up to 2-days against a 
freshly prepared standard each time 
Table 6.2.17 
Time in 
days 
% assay of 
Std 
preparation 
Difference 
% assay of test 
preparation 
Difference 
Test-1 Test-2 Test-1 Test-2 
Initial 100 NA 99.8 99.9 NA NA 
1 99.8 0.2 99.0 99.2 0.8 0.7 
2 98.9 1.1 98.7 98.5 1.1 1.3 
Acceptance Criteria: The % assay of Nisoldipine in standard and test preparation   
should not differ by more than 2.0 % from initial value. 
Conclusion: 
 The Reproducibility of the method comes under within the limits.  
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7. ROBUSTNESS 
a. Effect of variation in mobile phase composition 
To demonstrate the robustness, check the system suitability parameters by injecting 
system suitability solution and standard preparation, by using two mobile phases, one 
containing 10% increase in composition of organic solvent and other containing 10%  
decrease in the composition of organic solvent. Evaluate the system suitability 
parameters and % assay  
Table 6.2.18 
Suitability 
parameters 
Organic phase ratio Acceptance 
criteria 90% org. 100 % org. 110% org. 
Tailing factor 1.5 1.5 1.5 NMT 2 
 plate count 11019 11212 11045 NLT 3500 
 
If the acceptance criterion fails, narrow the organic phase composition range and 
report the organic phase composition range at which acceptance criteria passes. 
Table 6.2.19 
Mobile phase 
composition 
% assay 
Average % assay 
Trail-1 Trail-2 
25:50:25 99.4 99.0 99.2 
30:40:30 100.0 99.0 99.5 
35:30:35 100.3 99.8 100 
 
Acceptance criteria 
All system suitability parameters shall meet the requirements. 
The average %assay values should not differ by more than 2.0 when compared with 
that of the test values. 
 
b. Effect of variation in flow rate 
To demonstrate the robustness of method, check the system suitability parameters by 
injecting system suitability solution and standard preparation, into the HPLC system 
with 0.9 mL/min and 1.1mL/min. evaluate the system suitability parameters and % 
assay. 
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Table 6.2.20 
Suitability 
parameters 
Flow rate mL/min Acceptance 
criteria 0.9mL/min 1.0mL/min 1.1mL/min 
Tailing factor 1.1 1.0 1.2 NMT 2 
USP plate count 11031 11223 11256 NLT 3500 
 
If the system suitability fails, narrow the flow rate range and report the flow rate range 
at which system suitability passes. 
 
Table 6.2.21 
Flow rate in 
mL/min 
% assay 
Average % assay 
Trail-1 Trail-2 
0.9 96.6 96.6 99.6 
1.0 98.8 98.9 98.8 
1.1 100.2 99.9 100.1 
 
Acceptance criteria 
All system suitability parameters shall meet the requirements. 
The average %assay values should not differ by more than 2.0% when compared with 
that of the test values. 
 
c. Effect of variation in pH 
To demonstrate the robustness of method, check the system suitability parameters by 
injecting standard preparation, into the HPLC system at ±0.2 pH .Evaluate the system 
suitability parameters and % assay. 
Table 6.2.22 
Suitability 
parameters 
Observed values at pH Acceptance 
criteria 6.6 6.8 7.0 
Tailing factor 1.5 1.5 1.5 NMT 2 
Usp plate count 11154 11212 11145 
NLT 3500 
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If the system suitability fails, narrow the pH range and report the pH range at which 
system suitability passes. 
Table 6.2.23 
pH % assay  
6.6 99.3  
6.8 100.1  
7.0 100.4 
 
Acceptance criteria 
All system suitability parameters shall meet the requirements. 
The average %assay values should not differ by more than 2.0 when compared with 
that of the test values. 
d. Effect of variation in column temperature 
To demonstrate the robustness of method, check the system suitability parameters by 
injecting standard preparation into the HPLC system at 40°c temperature, 35°c and at 
45 °c . Evaluate the system suitability parameters and % assay. 
Table 6.2.24 
Suitability 
parameters 
Observed values at column temp. Acceptance 
criteria 28°c 30°c 32°c 
Tailing factor 1.5 1.5 1.4 NMT 2 
USP plate count 11019 11423 11405 NLT 3500 
Table 6.2.25 
Column oven 
temperature 
% assay 
28 °c 99.3 
30 °c 97.9 
32 °c 97.5 
 
Acceptance criteria 
All system suitability parameters shall meet the requirements. 
The average %assay values should not differ by more than 2.0 when compared with 
that of the test values. 
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e. Filter validation 
To demonstrate robustness of assay method, carry out filter validation using two 
different filters prepare test solution in triplicate. Centrifuge and filter different 
portions of the test preparation and inject into the HPLC system along with unfiltered 
standard. Calculate the percentage assay. 
Table 6.2.26 
Filter description 
filters 
1 2 
Manufactured by 
Advanced micro 
devices pvt ltd 
Advanced micro devices 
pvt ltd 
Lot no SYNN0602MNX104 NB417178 
Size 0.45um 0.45um 
 
 
Table 6.2.27 
Centrifuged Samples filtered 
through-filter 
Samples filtered through-
filter 
% assay % assay Difference % assay Difference 
99.8 99.6 0.2 99.4 0.4 
99.6 99.4 0.2 99.1 0.5 
99.7 99.6 0.1 99.5 0.2 
99.8 99.3 0.5 99.6 0.2 
Acceptance Criteria 
The difference of %assay result from centrifuged sample to filtered samples should be 
not more than 2.0. 
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6.3 DISSOLUTION 
 
Optimization of chromatographic conditions 
Suitable selection of the method depends upon the nature of the sample, its molecular 
weight and solubility. Hence the drugs selected in the present study polar in nature, RP-HPLC 
method was selected because of its simplicity. 
For the determination of wavelength for the estimation of Nisoldipine, UV spectrum was 
recorded in the range of 200-400 nm. After receiving the spectrum of standard, sample, placebo, 
wavelength of detection method was selected as 333nm. 
             The optimization of HPLC parameters was done by investigating the influence of the 
mobile phase composition while stationary phase, detection wavelength, injection volume , flow 
rate  and column oven temperature were set constant.  
In the case of Trail 1 pH6.8 Phosphate buffer: acetonitrile: methanol was selected as 
mobile phase at a ratio of 30:40:30 but resulted in no elution. Figure (7.1). In the case of Trail 2 
pH3 (near to log p value of Nisoldipine) buffer: acetonitrile was selected as mobile phase at a 
ratio of 50:50 but resulted in poor elution Figure (7.2). Hence pH3 buffer: Acetonitrile: methanol 
was selected as a mobile phase at a ratio of 20:60:20 and chromatograms were recorded in Trail 
3. While using methanol in the mobile phase, peak shape was good. But the retention time was 
too long and theoretical plate count also very less (Figure7.3). So in Trail 4 the above mobile 
phase ratio was adjusted in to 30:40:30. In the Trail 4 the peaks with good symmetry, optimized 
retention time, tailing factor were observed (figure7.4) and therefore this was selected as the 
mobile phase condition for this method the column thermostat was maintained at ambient 
temperature. Initially injection column was stabilized with the initial mobile phase concentration 
for 60 min. 
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Many trials on composition of buffer and organic phase were done to decide the ultimate 
composition of mobile phase. Results found are as follows 
Table no 6.3.1 
Composition of 
mobile phase. Retention time Tailing factor Theoretical plates 
PH6.8 
PHOSPHATEBUFFER
:ACN:Methanol(30:40:
30) 
No elution 
PH6.8 PHOSPHATE 
BUFFER: ACN(50:50) 
9.2 1.1 10536 
PH6.8 PHOSPHATE 
BUFFER: 
ACN:MeOH(20:60:20) 
4.2 1.4 5567 
PH6.8 PHOSPHATE 
BUFFER: 
ACN:MeOH(30:40:30) 
3.1 1.1 5989 
SELECTION OF COLUMN 
Keeping the mobile phase ratio 30:40:30 pH 3 buffer: Acetonitrile: Methanol, the 
chromatograms were recorded with C18 Column (Prontosil H (100 X 4.6mm) 3µm. At this 
column, the peaks were sharp. So this column was kept constant for the analysis (also tried with 
different particle size of stationary phase like 5µ, 1.8µ.)1.8µ column also produce good peak 
symmetry and retention time. Due to efficacy of column (life time) 3 µ was selected. 
Table 6.3.2 
Column Retention time Area 
Tailing 
factor Theoretical plates 
Prontosil C18 H 
(100*4.6mm)3µ 
3.1 1177890 1.0 5969 
Peerless Basic 
C18(100*4.6mm)1.8µ 
3.4 1179252 1.2 1304 
Develosil 
(150*4.6mm) 5µ 
4.2 1163862 1.5 1854 
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EFFECT OF FLOW RATE: 
  Keeping the mobile phase ratio 30:40:30 pH 3 buffer: Acetonitrile: Methanol, the 
chromatograms were recorded at a flow rate of 1.5ml/min. At this flow rate, the peaks were 
sharp and short retention time. So 1.5ml/min was kept constant for the analysis (flow rate 
0.8ml/min 1ml/min, up to 1.2ml/min were also tried, but did not give any satisfactory results). 
.Results Found Are As Follows 
Table no 6.3.3 
 
 
 
EFFECT OF COLUMN OVEN TEMPERATURE 
Keeping the mobile phase ratio 30:40:30 pH 3 buffer: Acetonitrile: Methanol, the 
chromatograms were recorded at an oven temperature at ambient (due to addition of SLS). At 
this temperature, the peaks were sharp. So Ambient temperature was kept constant for the 
analysis (column oven temperature 300C, 350C, 400C were also tried, but there is no effective 
changes in the retention time).Results Found Are As Follows.  
Table no 6.3.4 
 
 
 
 
 
Flow rate 
mL /min Peak shape Retention time Tailing factor 
Theoretical 
plates 
0.8 - - - - 
1.0 Good 4.3 1.0 6019 
1.2 Good 3.6 1.0 5705 
1.5 Excellent 3.1 1.0 5930 
Temp °c Peak shape 
Retention 
time 
Tailing 
factor 
Theoretical 
plates 
ambient Excellent 3.1 1.0 5992 
30°c Good 3.1 1.2 4663 
35oC Good 2.9 1.2 4069 
40°c Good 2.8 1.4 4982 
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SELECTION OF DISSOLUTION PROFILE 
Solubility studies  
Conduct solubility studies (saturation solubility) of the drug substance in dissolution media 
having pH between 1 to 8 
Table no 6.3.5 
 
S.NO Media Solubility (mg/mL) 
1 Purified water+0.5%SLS-250C 0.091 
2 Purified water+0.5%SLS-370C 0.115 
3 0.1N HCL+0.5%SLS-250C 0.069 
4 0.1N HCL+0.5%SLS-370C 0.079 
5 PH 6.8 Phosphate buffer+0.5%Tween 80-250C  0.074 
6 PH 6.8 Phosphate buffer+0.5%Tween 80-370C 0.072 
 
Dissolution medium 0.1N HCL+0.5%SLS can be selected as drug solubility studies and 
information from office of drug generic. 
SELECTION OF RPM                    
  Table no 6.3.6 
TIME(Hr/Min) % Drug release at 50 
Rpm 
% Drug release at 50 
Rpm 
2 7.4 8.2 
6 30.8 31.7 
12 68.1 74.8 
20 94.5 101.6 
24 101.6 102.1 
From the above result, maximum amount of %drug release can be obtained in 50 RPM itself. So 
50 RPM has selected. 
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Dissolution Profile Comparison by Using  
Similarity Factor 
                                  Among several methods investigated for dissolution profile 
comparison, f2 is the simplest. More and Flanner proposed a model independent mathematical 
approach to compare the dissolution profile using two factors, f1 (difference factor) and f2 
(similarity factor).it can be shown below. 
a) COMPARATIVE DRUG RELEASE PROFILES OF INNOVATOR & 
INHOUSE IN USP Type II, 50 RPM, pH 1.2 + 0.5% SLS, Sinkers 
Table no 6.3.7(A) 
 
 
 
 
 
 
 
 
 
 
 
 
                
Chart No:2 
    
                  
Time (h) Innovator In house 
0 0 0 
1 2.8 2.4 
2 7.3 7.1 
4 19.6 18.8 
6 35 32.7 
8 53.8 49.6 
12 79 77.9 
16 87.6 91.1 
18 89.1 91.7 
20 89.7 92 
24 88.7 91.5 
f2 (>50) 80.0 
f1 (<15) 4.4 
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Time 
(h) Innovator In house 
0 0 0 
1 5.4 3.5 
 2 12.7 10.9 
4 29.7 26.4 
6 49.7 42.2 
8 69.2 63.1 
12 97.3 94.7 
 16 98.9 92.7 
18 99.3 96.3 
20 99.3 96.6 
24 99.8 97.8 
f2 (>50) 67.1 
f1 (<15) 8.8 
COMPARATIVE DRUG RELEASE PROFILES OF INNOVATOR & INHOUSE IN 
USP Type II, 50 RPM, pH 4.5 + 0.5% SLS, Sinkers 
              Table no 6.3.7(b)                                               Chart No:3 
     
 
 
 
 
 
 
 
 
COMPARATIVE DRUG RELEASE PROFILES OF INNOVATOR & INHOUSE IN 
USP Type II, 50 RPM, pH 6.8 BUFFER + 0.5% SLS, Sinkers 
           Table no 6.3.7(c)                                                             Chart No:4 
Time 
(h) Innovator In house 
0 0 0 
1 2.9 15.6 
2 5.8 19.1 
4 28.9 60.1 
6 56.1 77.2 
8 79.4 86.8 
12 91.8 89.7 
16 93.7 91.7 
18 94.2 92.3 
20 92.8 93.8 
24 93.4 90.7 
f2 (>50) 36.0 
f1 (<15) 49.5 
0
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 6 7 8 9 10 11
Innovator
Inhouse
RESULTS AND DISSCUSION-DISSOLUTION 
 
   91 
 
COMPARATIVE DRUG RELEASE PROFILES OF  INNOVATOR & INHOUSE  IN 
USP Type II, 50 RPM, pH 7.5 BUFFER + 0.5% SLS, Sinkers 
Time (h) Innovator In house 
0 0 0 
1 6 15.7 
2 18.4 30 
4 48.4 51.7 
6 74.2 68.1 
8 87.5 80 
12 96.8 90.5 
16 96.9 94.5 
18 97.1 94.9 
20 97 95.3 
24 96.8 95 
f2 (>50) 54.3 
f1 (<15) 16.3 
                 
               Table no 6.3.7(d)                                                   Chart No:5 
 
COMPARATIVE DRUG RELEASE PROFILES OF  INNOVATOR &INHOUSE 
IN USP Type II, 50 RPM, Purified Water + 0.5%SLS, Sinkers 
 
              Table no 6.3.7(e)                                        Chart No:6 
Time (h) Innovator In house 
0 0 0 
1 11.5 9.8 
 2 26.2 23 
4 56 48.2 
6 83.6 68.5 
8 98.4 82.9 
12 99 96.3 
16 99.4 97.5 
18 99.5 97.5 
20 100 97.8 
24 101.4 98.2 
f2 (>50) 59.0 
f1 (<15) 14.7 
                                                            
0
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 6 7 8 9 10 11
Innovator
Inhouse
0
10
20
30
40
50
60
70
80
90
100
1 3 5 7 9 11
Innovator
Inhouse
RESULTS AND DISSCUSION-DISSOLUTION 
 
   92 
 
OPTIMIZED METHOD FOR DISSOLUTION 
Chromatographic system 
1. Liquid chromatograph equipped with a 333 nm UV detector. 
2. Column: 100 x 4.6 mm column that contains  3 µm packing of octadecyl silane 
chemically bonded to porous silica or ceramic micro particles (Prontosil H -100 x 
4.6 mm) 
3. Column temperature : Ambient 
4. Flow rate   :1.5 mL/min 
5. Injection volume  :50 µl 
6. Run time   :  5 mins 
 
Dissolution parameters 
                 1. Dissolution medium  : 0.1 N HCL+0.5%SLS 
                 2. Dissolution apparatus  : USP 2 Paddle 
                 3. RPM    : 50 RPM 
                 4. Dissolution volume  : 900 ML 
                 5. Time points   : 4, 8, 16, 24 
System Suitability 
Inject 20 µL portion of diluents (single injection) and standard solution (five replicate injections) 
into the chromatograph record the chromatograms and measure the responses for the major peak. 
The USP tailing factor for Nisoldipine peak should not be more than 2.0 
The column efficiency for Nisoldipine peak should be not less than 3500 theoretical plates. 
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The % RSD for the areas of Nisoldipine peak obtained from five replicate injections of standard 
solution should be not more than 2.0 
FORMULA  
CALCULATION 
                                                                                                 A × WS×4 ×900 ×P ×100 
Quantity of Nisoldipine dissolved in nth time interval (D) =   ------------------------------------------                         
                                      B×100 ×50 ×L ×100 
 
CALCULATION OF CORRECTION FACTOR    F (n-1)   = (D (n-1)/900) ×10 
CORRECTED RESULTS 
  
      n th time interval                           =   D(n-1)+F1+F2…….+F(n-1) 
Where,   A    =    peak area                                       B  = average standard area 
                            WS  = weight of working standard             p  = potency 
                             L     = label claim  
 SIMILARITY  FACTOR (f 2) 
f 2  =   50 X log {[ 1+(1/n)Σ  t  = 1 n ( R t -  Tt  )2] -0.5 X 100 
 DIFFERENCE FACTOR  (f 1)  
f 1     =    { [ Σ  t = 1 n (R t -  Tt  )]/ [ Σ  t = 1 n R t ]} X 100 
Where, n = number of time points  
 R t = Dissolution value of reference batch at time t. 
 T t = Dissolution value of test batch at time t 
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6.4 METHOD VALIDATION 
1. SYSTEM PRECISION 
Inject ten replicate injections of Nisoldipine standard preparation into HPLC system and 
calculate relative deviation of Nisoldipine peak area. 
Table 6.4.1 
INJECTION NO. NISOLDIPINE PEAK AREA 
1 1183809 
2 1184552 
3 1171419 
4 1160887 
5 1180634 
6 1189539 
7 1178208 
8 1173146 
9 1181353 
10 1173940 
Average 1171749 
% RSD 0.38 
 
Acceptance Criteria: The % RSD for ten replicate injections should be NMT 1% 
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SYSTEM SUITABILITY 
Prepare system suitability solution as per the developed method and inject into HPLC system 
Table 6.4.2 
System suitability 
parameters Observed value Acceptance limit 
USP tailing factor 1.4 NMT 2.0 
USP plate count 5689 NLT 3500 
% RSD 0.71 NMT 2.0% 
 
Acceptance criteria 
1) The % RSD for the peak area from ten replicate injections of Nisoldipine should be NMT 
2% 
 2)   The %RSD for the retention time of Nisoldipine from ten replicate injection of 
       Standard Solution should not be more than 2% 
3)    The number of theoretical plates (N) for the Nisoldipine peak is NLT 3500 
4)    The Tailing factor (T) for the Nisoldipine peak is NMT 2.0 
Observation 
1)    The % RSD for the peak area from ten replicate injections of Nisoldipine is 0.38 
2)    The %RSD for the retention time of Nisoldipine from ten replicate injection of   
       Standard   Solution should 0.20 
3)   The number of theoretical plates (N) for the Nisoldipine peak is 5689 
4)   The Tailing factor (T) for the Nisoldipine peak is 1.4 
Conclusion: It passes the system suitability 
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2. SPECIFICITY 
PLACEBO INTERFERENCE (selectivity) 
Perform dissolution in triplicate on placebo with equivalent concentration to that of the test 
concentration and evaluate the interference for each of the placebo preparations. 
Table 6.4.3 
Sample no % interference 
1 0 
2 0 
3 0 
 
Acceptance criteria 
No Interference from Placebo shall be observed at the retention time of main peak. 
Conclusion  
% interference from placebo was found to be within the acceptance criteria 
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3. PRECISION 
REPEATIBILITY  
Determine the precision of the method by performing dissolution on six samples of homogenous 
blend prepared by mixing placebo and Nisoldipine raw material. 
Table 6.4.4 
Sample 
no. Area Avg. area 
% 
Dissolution 
1 
1182521 1183207 
 
99.1 
1183892 
2 
1189305 1186164 
 
99.5 
1183022 
3 
1179357 1176398 
 
98.5 
1173439 
4 
1187774 1185910 
 
99.3 
1184045 
5 
1187488 1189771 
 
100.1 
1192053 
6 
1187556 
1189565 100.1 
1191573 
Average 
 
1181923 99 
% RSD 0.4 0.5 
     Acceptance criteria 
1) The Average Assay should be not less than 95%. 
2) The relative standard deviation of assay should not be more than 2.0%. 
    Observation:   The Average % Dissolution is 99 
                  The relative standard deviation of assay is 0.50 
   Conclusion   :    The results obtained are well within the acceptance criteria. Therefore method   
                              is Precise. 
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4. ACCURACY        
To validate, the dissolution method can accurately quantify Nisoldipine with in the excipients, 
proportionally spiking various amounts of Nisoldipine raw material and the placebo at various 
concentrations ranging from 25 % to 150 %. 
Table 6.4.5 
Sample no Spike level % mg added mg found % recovery avg. % recovery 
%RSD 
 
1 
 
25 
 
8.6 
8.6 100 
99.4 1.0 8.5 98.3 
8.6 100 
 
2 
 
50 
17 
 
17.1 100.5 
100.1 0.3 17 100 
17 100 
 
3 
 
75 
25.6 
 
25.4 99.2 
99.7 
 
0.5 25.6 100.0 
25.6 100.0 
 
4 
 
100 
34 
34 100 
100 0.0 34 100 
34 100 
 
5 
 
125 
 
42.6 
42.6 100 
99.8 
 
0.3 42.4 99.5 
42.6 100 
 
 
6 
150 51 
51.1 100.1 
99.9 0.2 50.9 99.8 
51 100 
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Acceptance Criteria 
 The average recovery of Nisoldipine at each spike level should not be less than 95%  
Conclusion  
The % recovery at each level is found to be within the limits. 
Hence the method is accurate in the specified range 
5. LINEARITY OF TEST METHOD 
To demonstrate the linearity of dissolution method, inject in duplicate five standard solutions 
with concentration equivalent to 25 % to 150% target concentration of standard. Plot a graph to 
concentration versus average peak area. Table 6.4.6 
S. No. Conc (µg/mL) Average area 
1 10 309421 
2 20 596984 
3 30 870176 
4 40 1185569 
5 50 1485569 
 
6 
 
60 1790353 
Coefficient correlation       =         0.9997 
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Chart No: 7 
 
 
Acceptance criteria 
Coefficient of correlation shall be NLT 0.999 
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6. RUGGEDNESS 
a. System to System Variability  
To demonstrate the ruggedness of dissolution method, carryout system to system variability on 
two different dissolution systems of different make and perform dissolution. 
Table 6.4.7 
System suitability 
Observed values 
Acceptance criteria System-1 
(Labindia) 
System-2 
(Electrolab) 
Tailing factor 1.1 1.1 NMT 2 
Theoretical plate count 5655 5589 NLT3500 
 
Table 6.4.8 
 
 
Acceptance criteria 
The average dissolution should be not less than 95.0%.The relative standard deviation of 
dissolution should be not more than 2.0% on both the systems. 
The overall RSD for 6 values shall be NMT 2.0 %. 
Sample no 
% Dissolution 
System-1 System-2 
1 99.7 99.5 
2 99.8 99.8 
3 99.7 99.8 
Average 99.7 99.7 
%RSD 0.10 0.10 
Overall % RSD 
0.10 
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b. Column to Column Variability 
To demonstrate the ruggedness of dissolution method, carryout column to column variability by 
two different columns 
Table 6.4.9 
System 
suitability 
Observed values Acceptance 
Criteria Column-1 
(Prontosil H) 
Column-2 
(Peerless basic) 
Tailing factor 1.2 1.1 NMT 2 
Theoretical 
plate count 5785 5258 NLT 3500 
 
Table 6.4.10 
Sample no 
% Dissolution 
Column-1 Column-2 
1 99.8 99.8 
2 99.7 99.8 
3 99.8 99.9 
Average 99.8 99.8 
%RSD 0.13 0.05 
Overall % RSD 0.10 
 Acceptance criteria 
The average dissolution should be not less than 95%. 
The relative standard deviation of dissolution should not be more than 2.0% on both the 
columns. 
The overall RSD for 6 values shall be NMT 2.0 %.  
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c. Analyst to analyst variability  
To demonstrate the ruggedness of dissolution method, carryout analyst to analyst variability by 
two different analyst 
Table 6.4.11 
System suitability 
Observed values 
Acceptance criteria 
Analyst-1 Analyst-2 
Tailing factor 1.1 1.1 NMT 2 
Theoretical plate 
count 5489 5658 NLT3500 
 
Table 6.4.12 
Sample no 
% dissolution 
Analyst -1 Analyst -2 
1 99.0 98.9 
2 98.7 99.8 
3 99.7 98.8 
Average 99.2 99.4 
%RSD 0.46 0.49 
Overall % RSD 0.47 
Acceptance criteria 
The average dissolution should be not less than 95.0%. 
The relative standard deviation of dissolution should be not more than 2.0%. 
The overall RSD for 6 values shall be NMT 2.0 %.  
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7. ROBUSTNESS 
a. EFFECT OF VARIATION IN FLOW RATE 
To demonstrate the robustness of method, check the system suitability parameters by injecting 
system suitability solution and standard preparation, into the HPLC system with 0.8 mL/min and 
1.2mL/min.evaluate the system suitability parameters and % dissolution. 
Table 6.4.13 
Suitability parameters 
Flow rate mL/min 
Acceptance criteria 
1.4 1.6 
Tailing factor 1.1 1.0 NMT 2 
Theoretical plate count 5798 5705 NLT 3500 
% RSD 1.5 0.87 NMT 2.0% 
 
If the system suitability fails, narrow the flow rate range and report the flow rate range at which 
system suitability passes. 
Table 6.4.14 
Flow rate in 
mL/min 
% dissolution 
Avg.%  dissolution 
Trail-1 Trail-2 
1.4 99.9 100.2 100.0 
1.6 99.4 99.4 99.4 
Acceptance criteria 
All system suitability parameters shall meet the requirements. 
The average % dissolution values should not differ by more than 2.0%. 
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b. EFFECT OF VARIATION IN pH 
To demonstrate the robustness of method, check the system suitability parameters by injecting 
standard preparation, into the HPLC system at +/- 0.2 pH .evaluate the system suitability 
parameters and % dissolution. 
Table 6.4.15 
Suitability 
parameters 
Observed values at pH 
Acceptance criteria 
2.8 3.0 3.2 
Tailing factor 1.1 1.2 1.1 NMT 2 
Theoretical plate 
count 5023 5569 5456 NLT 3500 
% RSD 0.5 0.51 0.79 NMT 2.0% 
 
If the system suitability fails, narrow the pH range and report the pH range at which system 
suitability passes. 
Table 6.4.16 
pH 
% dissolution 
Avg.% dissolution 
Trail-1 Trail-2 
2.8 102.3 101.9 102.1 
3.0 99.9 100.0 99.9 
3.2 99.1 98.8 98.9 
 
Acceptance criteria 
All system suitability parameters shall meet the requirements. The average % dissolution values 
should not differ by more than 2.0 when compared with that of the test values. 
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C. FILTER VALIDATION 
To demonstrate robustness of dissolution method, carry out filter validation using two different 
filters. Prepare test solution in triplicate. Centrifuge and filter different portions of the test 
preparation and inject into the HPLC system along with unfiltered standard. Calculate the 
percentage dissolution. 
Table 6.4.17 
Filter description 
Filters 
Filter 1 Filter 2 
Manufactured by 
Advanced micro devices 
pvt ltd 
Advanced micro devices pvt ltd 
Lot no SYNN0602MNX104 NB417178 
Size 0.45um 0.45um 
 
Table 6.4.18 
% dissolution 
( labindia) 
Samples filtered through-
filter 1 
Samples filtered through-filter 2 
% dissolution Difference % dissolution Difference 
98.4 97.4 1.0 97.6 0.8 
98.3 97.3 1.0 97.5 0.8 
98.3 97.4 0.9 97.0 1.3 
Acceptance Criteria 
The difference of % dissolution result between centrifuged sample and filtered samples should 
be not more than 2.0 
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9. SINK CONDITION 
Perform dissolution on Nisoldipine drug substance in dissolution medium by adding 102mg of 
Nisoldipine to dissolution vessel at room temperature with 150 rpm. Calculate the % dissolution 
of Nisoldipine. 
Table 6.4.19 
Sample 
no 
‘mg of Nisoldipine 
added’ 
‘mg of Nisoldipine 
found’ 
%dissolution 
01 102 82.5 80.88 
02 102.2 82.3 80.68 
average 
102.1 
 
82.4 
 
100 
 
Acceptance criteria 
The amount of Nisoldipine dissolved shall not be less than 60mg. 
 
CHROMATOGRAMS 
 
   108 
 
SELECTION OF WAVELENGTH 
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FIG-1.2 
 
FIG-1.3 
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                    TRAIL 1 (FIG NO: 2.1) 
 
                        TRAIL-2 (FIG NO: 2.2) 
 
                         TRAIL‐3 (FIG NO: 2.3) 
                         TRAIL‐4 (FIG NO: 2.4) 
 
                           TRAIL‐5 (FIG NO: 2.5) 
CHROMATOGRAMS 
 
   111 
 
 
 
 
VALIDATION CHROMATOGRAMS-ASSAY 
SYSTEM PRECISION 
 
 
FIG NO: 3 
 
CHROMATOGRAMS 
 
   112 
 
SYSTEM SUITABILITY 
 
FIG NO 3.1 
SPECIFICITY 
 
FIG NO: 3.2 
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FIG NO: 3.3(B) 
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FIG NO: 3.3(C) 
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 FIG NO: 3.3(D) 
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 FIG NO: 3.3(E)
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 FIG NO: 3.3(F)
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 FIG NO: 3.3(G)
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 FIG NO: 3.3(H) 
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 FIG NO: 3.3(I)
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 FIG NO: 3.3(J)
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 FIG NO: 3.3(K) 
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 FIG NO: 3.3(L) 
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METHOD LINEARITY 
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ACCURACY 
    
FIG NO: 6 
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DISSOLUTION 
 
          TRAIL-1 (FIG NO: 7.1) 
 
             TRAIL-1 (FIG NO: 7.2) 
 
            TRAIL-1 (FIG NO: 7.3) 
 
              TRAIL-1 (FIG NO: 7.4) 
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VALIDATION CHROMATOGRAMS-DISSOLOUTION 
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8. SUMMARY AND CONCLUSION 
 SUMMARY 
DEVELOPED CHROMATOGRAPHIC CONDITIONS FOR ASSAY ARE AS FOLLOWS  
1. SELECTION OF WAVELENGTH 
After reviewing chromatograms and peak purity chromatograms a wavelength of 333nm is 
selected as the wavelength for this drug. At this wavelength baseline noise is less and peak purity 
of drug is more. 
2. SELECTION OF COLUMN 
It was found that the peak shape, retention time, tailing factor, column efficiency are good with 
Peerless Basic, and hence Peerless Basic C18 (100 × 4.6 mm) 1.8µm column is selected. (Table 
No: 6.1.2) 
3. OPTIMIZATION OF MOBILE PHASE COMPOSITION 
Good Peak shape, retention time, tailing factor, theoretical plates are obtained with pH 6.8 
phosphate buffer: ACN: MeOH (30:40:30) .Hence it was finalized. 
4. SELECTION OF FLOW RATE  
After reviewing the results it was found that 1.0 mL is resulted with good peak shape, retention 
time, and good peak symmetries. Hence it was taken as the flow rate for the method. (Table No: 
6.1.3) 
5. SELECTION OF COLUMN TEMPERATURE 
Retention time, peak area, plate count was found to be good at 30°c.(Table No:6.1.4) 
6. OPTIMIZATION OF SAMPLE PREPARATION   
From this data it is concluded that preparation of test is to be done   MeOH: pH3 buffer (50:50). 
The % assay is more when the sample preparation was done in MeOH: pH3 buffer (50:50), 
hence this composition was selected as diluent. 
7. ADJUSTING THE INJECTION VOLUME 
Good peak shape, retention time, and more theoretical plates are obtained when an injection 
volume of 20 µl was used.(Table No: 6.1.5) 
8. ESTABLISHMENT OF SYSTEM SUITABILITY 
As the % RSD is below 2% .we can say the chromatographic system is adequate for the analysis 
to be done. 
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9. INSTRUMENT 
Shimadzu HPLC system with UV detector and auto sampler. 
 
VALIDATION OF ASSAY PARAMETERS 
1. SYSTEM PRECISION 
The %RSD of ten injections was found to be 0.0% (acceptance criteria 1.0%), it concludes 
the system precision was passed. (Table No 6.2.1, Fig No 3) 
System Suitability (Table No 6.2.2, Fig No 3.1) 
All the system suitability parameters are passed 
2. SPECIFICITY 
a. Placebo Interference 
Main peak have no interference with placebo peak, hence no placebo interference. 
(Table No 6.2.3, Fig No 3.2) 
b. Interference From Degradants 
Purity angle is less than purity threshold and Nisoldipine peak does not have any flag 
in purity results. (Table No 6.2.4, Fig No 3.3(A) - Fig No 3.3(L) 
3. LINEARITY OF METHOD 
The coefficient of correlation was found to be 0.9998, hence the method response was found 
to be linear. (Table No 6.2.5, Fig No 4, Chart No: 1) 
4. PRECISION 
Repeatability  
The relative standard deviation of % assay results was found to be 0.10, and the % assay 
results of Nisoldipine are within 95% and 105%, hence it was concluded that the method 
shows repeatability. (Table No 6.2.6, Fig No 5) 
5. ACCURACY 
The average % recovery of Nisoldipine at each spike level was not less than 95% and not 
more than 105%, hence it was concluded that the method shows accuracy. (Table No 6.2.7, 
Fig No 6) 
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6.    RUGGEDNESS 
a. Analyst To Analyst Variability 
b. All the individual assay values of Nisoldipine are within 95% to 105% and the 
relative standard deviation of % assay results are not more than 2%, hence there is no 
analyst to analyst variability. (Table No 6.2.8&6.2.9) 
c. System To System Variability  
All the individual assay values of Nisoldipine are within 95% to 105% and the 
relative standard deviation of % assay results are not more than 2%, hence there is no 
system to system variability. (Table No 6.2.10&6.2.11) 
d. Column to column variability 
All the individual assay values of Nisoldipine are within 95% to 105% and the 
relative standard deviation of % assay results are not more than 2%, hence there is no 
column to column variability. (Table No 6.2.12&6.2.13) 
e. Bench top stability of mobile phase 
The % assay results of Nisoldipine not differ from initial value by more than 2%, 
hence it was concluded the mobile phase was stable for two days. (Table No 
6.2.14&6.2.15) 
f. Bench top stability of Nisoldipine standard and test solution  
The % assay of Nisoldipine in standard and test preparation does not differ by more 
than 2% from initial value, hence it was concluded the standard and the sample 
solutions were stable for two days. (Table No 6.2.16) 
g. Refrigerator stability of samples 
The % assay of Nisoldipine in standard and test preparation does not differ by more 
than 2% from initial value, hence it was concluded that the standard and sample 
solutions were stable for two days under refrigeration. (Table No 6.2.17) 
6. ROBUSTNESS 
a. Effect of variation in mobile phase composition 
The average % assay values with the  variation of 10% composition of organic phase 
does not differ by more than 2%when compared to test method values ,hence it was 
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concluded that there is no effect of variation in mobile phase composition on % assay. 
(Table No 6.2.18&6.2.19) 
b. Effect of variation in flow rate 
The average % assay values with the  variation of  ±0.1mL/min does not differ by 
more than  2% when compared to test method values, hence it was concluded that 
there is no effect of variation in flow rate on % assay. (Table No 6.2.20&6.2.21) 
c. Effect of variation in pH of buffer in mobile phase  
The average % assay values with the  variation of ±0.2 pH does not differ by more 
than  2% when compared to test method values, hence it was concluded that there is 
no effect of variation in pH on % assay. (Table No 6.2.22&6.2.23) 
d. Effect of variation in column temperature 
The average % assay values with the  variation of  5°c of column temperature  does 
not differ by more than 2% when compared to test method values, hence it was 
concluded that there is no effect of variation in column temperature on % assay. 
(Table No 6.2.24&6.2.25) 
7. FILTER VALIDATION 
The difference in % assay of filtered sample and centrifuged sample is not more than 2 %, 
hence it was concluded that there is no interference due to filters. (Table No 6.2.26&6.2.27) 
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Results of Assay Method Validation of Nisoldipine Tablets 
Table No: 8.1.1 
S.No Parameters Observation Acceptance Criteria Passes/ Fail 
1. 
 
1.1 
1.2 
 
Precision 
 
System Precision 
Method Precision 
 
 
 
0.15 
0.10 
 
Percentage relative 
standard deviation 
(%RSD) is not more 
than 2.0 
 
Passes 
 
2. 
 
Specificity 
 
No peak elute 
 
No peak elutes at the 
retention time of main 
peak in the blank and 
placebo 
 
Passes 
 
 
 
 
 
3. 
Forced Degradation 
 
a. Degradation By       
Hydrochloric Acid 
b. Degradation By 
Sodium Hydroxide 
c. Degradation By 
Hydrogen Per- 
Oxide 
d. Degradation by 
Thermal Heat. 
e. Degradation By 
Exposing Light 
 
 
Well within the limit 
 
 
 
 
 
Purity angle should be 
less than purity 
threshold. 
 
 
 
 
 
 
 
Passes 
 
4. 
 
Linearity 
Correlation 
coefficient-0.9998 
Correlation coefficient 
(r ) is not less than 
0.999 
 
Passes 
5. Accuracy The percentage  
recovery was found 
between 99.6 – 
99.9% 
The percentage  
Recovery at each level 
is between 98.0-
102.0% 
 
Passes 
 
6. 
 
Solution Stability 
 
Well within the limit 
 
 
Cumulative %RSD is 
not more than 2.0 
 
Passes 
 
7. 
 
Filter Interference 
Well within the limit 
The percentage 
difference is not more 
than 2.0 
 
Passes 
 
8. 
 
Robustness Well within the limit 
Overall percentage 
Relative standard 
deviation  (%RSD) is 
not more than 2.0 
 
 
Passes 
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DEVELOPED CHROMATOGRAPHIC CONDITIONS FOR DISSOLUTION ARE AS 
FOLLOWS  
1. SELECTION OF WAVELENGTH 
After reviewing chromatograms and peak purity chromatograms a wavelength of 333nm is 
selected as the wavelength for this drug. At this wavelength the response of the drug is more 
and no interferences. 
2. SELECTION OF COLUMN 
It was found that the peak shape, retention time, tailing factor, column efficiency are good 
with Prontosil H, and hence Prontosil (100 × 4.6 mm) 3µm column is selected. (Table No: 
6.3.2) 
3. OPTIMIZATION OF MOBILE PHASE COMPOSITION 
Good Peak shape, retention time, tailing factor, theoretical plates are obtained with pH 
3buffer: ACN: MeOH (30:40:30) .Hence it was finalized. 
4. SELECTION OF FLOW RATE  
After reviewing the results it was found that 1.5 mL is resulted with good peak shape, 
retention time, and good peak symmetries. Hence it was finalized. (Table No: 6.3.3) 
5. SELECTION OF COLUMN TEMPERATURE 
Retention time, peak area, plate count was found to be good at ambient temperature.(Table 
No: 6.3.4) 
6. OPTIMIZATION OF SAMPLE PREPARATION   
As the % drug release is more in 0.1 N HCL+0.5%SLS, it was selected as diluent for sample 
preparation. 
7. ADJUSTING THE INJECTION VOLUME 
Good peak shape, retention time, and more theoretical plates are obtained when an injection 
volume of 50 µl was used. 
8. OPTIMIZATION OF STANDARD PREPARATION 
       From the solubility studies maximum solubility of drug was found in 0.1 N    
       HCL+0.5%SLS, hence it was used as diluent for extraction of drug. 
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8. SELECTION OF DISSOLUTION PARAMETERS 
Dissolution parameters like Medium, RPM, Medium volume, Time points, Apparatus can 
select from office of generic drug and confirmed by similarity factor studies.(Table 
No:6.3.7(a)-6.3.7(e)&Chart No:2-6). 
 
VALIDATION OF DISSOLUTION METHOD 
1. SYSTEM PRECISION 
The %RSD of ten injections was found to be 0.38 (acceptance criteria 1.0%), it concludes the 
system precision was passed. (Table No 6.4.1) 
System Suitability 
All the system suitability parameters are passed (Table No 6.4.2, Fig No 8) 
2. SPECIFICITY 
Placebo Interference 
Main peak have no interference with placebo peak, hence no placebo interference. (Table No 
6.2.3, Fig No 9) 
3. PRECISION OF THE TEST METHOD 
Repeatability :The average % dissolution values are not less than 95%,and the relative standard 
deviation of dissolution values was found to be 0.1%( acceptance limit 5%),it can be concluded 
that the method shows repeatability. (Table No 6.4.4, Fig No 11) 
4. ACCURACY 
The average % recovery of Nisoldipine at each spike level was not less than 95%, hence it was 
concluded that the method shows accuracy. (Table No 6.4.5) 
5. LINEARITY OF TEST METHOD 
As the correlation coefficient was found to be 0.9997, it was concluded the developed method 
shows linearity. (Table No 6.4.6, Fig No 10, Chart No: 7) 
6. RUGGEDNESS 
a. System to System Variability  
The average dissolution values are not less than 95%, and the relative standard deviation of 
dissolution are not more than 2% by both the systems, hence it was concluded that there is no 
system to system variability. (Table No 6.4.7&6.4.8) 
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 b. Column to column variability 
The average dissolution values are not less than 95%, and the relative standard deviation of 
dissolution are not more than 2% by both the columns, hence it was concluded that there is no 
column to column variability. (Table No 6.4.9&6.4.10) 
c. Analyst to Analyst Variability 
The average dissolution values are not less than 95%, and the relative standard deviation of 
dissolution are not more than 2% by both the analysts, hence it was concluded that there is no 
analyst to analyst variability. (Table No 6.4.11&6.4.12) 
7. ROBUSTNESS 
a. Effect of variation in flow rate 
The average % assay values with the  variation of  ±0.1mL/min does not differ by more than  2% 
when compared to test method values, hence it was concluded that there is no effect of variation 
in flow rate on % assay. (Table No 6.2.13&6.2.14) 
b. Effect of variation in pH of buffer in mobile phase  
The average % assay values with the  variation of ±0.1 pH does not differ by more than  2% 
when compared to test method values, hence it was concluded that there is no effect of variation 
in pH on % assay. (Table No 6.2.15&6.2.16) 
c. Filter Validation 
The difference between % dissolution of filtered sample and centrifuged sample is not more than 
2 %, hence it was concluded that there is no interference due to filters. (Table No 6.4.17&6.4.18) 
8. SINK CONDITION 
‘mg’ of Nisoldipine recovered is not less than 60mg. (Table No 6.4.19, Fig No 12) 
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Results of Dissolution Method Validation of Nisoldipine Tablets 
Table No: 8.1.2 
 
  
 
 
 
 
 
S.No Parameters Observation Acceptance Criteria Passes/ Fail 
1. 
 
1.1 
1.2 
 
Precision 
 
System Precision 
Method Precision 
 
 
 
0.38 
0.50 
 
Percentage relative 
standard deviation 
(%RSD) is not more than 
2.0 
 
Passes 
 
2. 
 
Specificity 
 
No peak elute 
 
No peak elutes at the 
retention time of main 
peak in the blank and 
placebo 
 
Passes 
 
3. 
 
Linearity 
Correlation coefficient 
is 
0.9997 
Correlation coefficient (r 
) is not less than 0.999 
 
Passes 
4. Accuracy 
The percentage  
recovery was found 
between 99.4 – 100.1% 
The percentage  
Recovery at each level is 
between 95.0-105.0% 
 
Passes 
 
5. 
 
Filter Interference Well within the limit 
The percentage 
difference is not more 
than 2.0 
 
Passes 
 
6. 
 
Robustness Well within the limit 
Overall percentage 
Relative standard 
deviation  (%RSD) is not 
more than 2.0 
 
 
Passes 
7. Sink condition 
The amount of 
Nisoldipine dissolved 
80mg. 
 
The amount of 
Nisoldipine dissolved 
shall not be less than 
60mg. 
 
Passes 
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CONCLUSIONS 
ASSAY 
An isocratic RP- HPLC method for analysis of Nisoldipine in pharmaceutical dosage form has 
been developed and validated. Best separation was achieved on a PEERLESS BASIC C18 (100 
× 4.6 mm) 1.8µm column using a mobile phase composition of pH 6.8 buffer: Methanol: ACN 
(30:30:40) at a flow rate of 1.0 mL/min. UV detection was performed at 333 nm. The method 
was validated for specificity, linearity, precision, accuracy, robustness, ruggedness & solution 
stability according ICH guidelines. The calibration plot was linear over the concentration range 
12.5-75ppm with correlation coefficient 0.9998. The accuracy was good. The HPLC method 
developed is accurate, precise, reproducible, specific, and stability indicating. The method is 
linear over a wide range, economical and utilizes a mobile phase which can be easily prepared. 
All these factors make this method suitable for quantification of Nisoldipine in bulk drugs and in 
pharmaceutical dosage forms without interference. It can therefore be concluded that use of the 
method can save much time and money and it can be used even in small laboratories with very 
high accuracy and precision. 
DISSOLUTION 
An isocratic RP- HPLC method for analysis of Nisoldipine in pharmaceutical dosage form has 
been developed and validated. Best separation was achieved on a PRONTOSIL C18 H (100 × 
4.6 mm) 3µm column using a mobile phase of composition of pH 3buffer: ACN: Methanol 
(30:40:30) at a flow rate of 1.5mL/min. UV detection was performed at 333 nm. The method was 
validated for specificity, linearity, precision, accuracy, robustness, ruggedness & solution 
stability according ICH guidelines. The calibration plot was linear over the concentration range 
10-60ppm with correlation coefficient 0.9997. The accuracy was good. . The data validation 
shows that the RP-HPLC method is accurate, robust and possesses excellent linearity and 
precision characteristics. This method can be successfully used for the quantitation of 
Nisoldipine as active substance, in dissolution studies and in tablet dosage forms. So it can be 
concluded that the developed method can be easily applied for the routine quality control 
analysis of Nisoldipine drug and it’s Formulation. 
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